Method for screening for autoimmune disease by identifying polymorphisms in il-12 p40

ABSTRACT

A method of screening mammals for an autoimmune disease or a predisposition to said disease (e.g diabeties). The method consists of identifying polymorphisms in IL-12 p40 and linking them to the disease condition.

FIELD OF THE INVENTION

[0001] The present invention relates generally to a method of screening mammalian animals for a disease condition or a predisposition for the development of a disease condition. More particularly, the present invention provides a method of screening for a disease condition or a predisposition for the development of a disease condition characterised by Th1/Th2 dysregulation. Disease conditions contemplated herein include autoimmune conditions such as, but not limited to, diabetes. The present invention is predicated in part on the determination of the presence of a particular form of IL-12 subunit or linkage between an IL-12 subunit and the disease condition.

BACKGROUND OF THE INVENTION

[0002] Bibliographic details of the publications referred to by author in this specification are collected at the end of the description.

[0003] The reference to any prior art in this specification is not, and should not be taken as, an acknowledgment or any form of suggestion that that prior art forms part of the common general knowledge in Australia.

[0004] Autoimmune diseases result from the body's immune system mounting an immune response to “self” via the aberrant activation of B cells and/or one or more of the subclasses of T cells. The classes of T cells can be defined broadly according to their requirement for particular molecules encoded by the major histocompatibility complex (MHC), and by their function. The class of T cells restricted by MHC class II molecules are generally referred to as “helper” T (referred to herein as “Th”) cells, and can be further divided into two main subclasses depending on the type of immune response which they mediate. These subclasses are referred to as Th1 and Th2, the former subclass mediating cellular immune response and the later mediating an antibody immune response.

[0005] There is increasing evidence that some disease states, including autoimmune diseases, may result from dysregulation of Th1/Th2 status. Insulin dependent diabetes melitis (IDDM), for example, results from the dysregulation of T cells in that they may be mediated by an imbalance towards Th1 and Th2 type responses, respectively. Although a number of immunological influences which affect Th1 and Th2 responses have been identified, such as the influence of the cytokines interleukin-10 and interleukin-12 (herein referred to as “IL-12”), the precise molecular mechanisms of regulating the division of Th cells into these subclasses together with their functional regulation has not been elucidated.

[0006] IL-12 is comprised of two subunits—p35 and p40. In work leading up to the present invention, the inventors have identified two allelic variants of the IL-12 p40 subunit. Analysis of distribution of these variants in the population has resulted in the surprising correlation of genetic variation in the IL-12 p40 genes with diseases having a bias in T cell response in terms of the Th subtype of the response. In accordance with the present invention, the inventors have identified a method of screening for an individual with a disease condition or predisposition for the development of a disease condition characterised by Th1/Th2 dysregulation. The developments described herein further facilitate the design of methodology to screen for individuals exhibiting resistance to the development of a disease condition characterised by Th1/Th2 dysregulation. In a further aspect there is now facilitated the development of methods of therapeutically and/or prophylactically treating such disease conditions.

SUMMARY OF HE INVENTION

[0007] Throughout this specification and the claims which follow, unless the context requires otherwise, the word “comprise”, and variations such as “comprises” and “comprising”, will be understood to imply the inclusion of a stated integer or step or group of integers or steps but not the exclusion of any other integer or step or group of integers or steps.

[0008] The subject specification contains nucleotide sequence information prepared using the programme PatentIn Version 2.0, presented herein after the bibliography. Bach nucleotide sequence is identified in the sequence listing by the numeric indicator <210> followed by the sequence identifier (e.g. <201>1, <210>2, etc). The length, type of sequence (DNA, etc) and source organism for each nucleotide sequence is indicated by information provided in the numeric indicator fields <211>, <212> and <213>, respectively. Nucleotide sequences referred to in the specification are defined by the information provided in numeric indicator field <400> followed by the sequence identifier (e.g. <400>1, <400>2, etc).

[0009] One aspect of the present invention provides a method of determining the presence of a disease condition or a predisposition for the development of a disease condition in a mammalian animal said method comprising screening for the presence of a form of IL-12 p40 genetic sequence or derivative thereof or its expression product wherein the presence of said form of IL-12 p40 genetic sequence or derivative thereof or its expression product is indicative of the presence of the disease condition or the propensity to develop said disease condition.

[0010] Another aspect of the present invention provides a method of determining the presence of a disease condition characterised, exacerbated or otherwise associated with Th1/Th2 dysregulation or a predisposition for the development of a disease condition characterised, exacerbated or other associated with Th1/Th2 dysregulation in a mammalian animal said method comprising screening for the presence of a form of IL-12 p40 genetic sequence or derivatives thereof or its expression product wherein the presence of said form of IL-12 p40 genetic sequence or derivative thereof or its expression product is indicative of the presence of the disease condition or the propensity to develop said disease condition.

[0011] Still another aspect of the present invention provides a method of determining the presence of a disease condition characterised, exacerbated or otherwise associated with Th1/Th2 dysregulation or a predisposition for the development of a disease condition characterised, exacerbated or otherwise associated with Th1/Th2 dysregulation in a mammalian animal said method comprising screening for the presence of an allelic form of IL-12 p40 genetic sequence or derivative thereof or its expression product wherein the presence of said allelic form of IL-12 p40 genetic sequence or derivative thereof or its expression product is indicative of the presence of the disease condition or the propensity to develop said disease condition.

[0012] Yet another aspect of the present invention provides a method of determining the presence of a disease condition characterised, exacerbated or otherwise associated with Th1/Th2 dysregulation or a predisposition for the development of a disease condition characterised, exacerbated or otherwise associated with Th1/Th2 dysregulation in a mammalian animal said method comprising screening for the presence of the Taq1⁺ allelic form of IL-12 p40 genetic sequence or derivative thereof or its expression product wherein the presence of said Taq1⁺ allelic form of IL-12 p40 genetic sequence or derivative thereof or its expression product is indicative of the presence of the disease condition or the propensity to develop said disease condition.

[0013] Even more preferably said IL-12 p40 Taq1⁺ allelic form comprises the nucleotide sequence substantially as set forth in<400>1.

[0014] Still yet another aspect of the present invention provides a method of determining the presence of a disease condition characterised, exacerbated or otherwise associated with Th1/Th2 dysregulation or a predisposition for the development of a disease condition characterised, exacerbated or otherwise associated with Th1/Th2 dysregulation in a mammalian animal said method comprising screening for the presence of the Taq1⁻ allelic form of IL-12 p40 genetic sequence or derivative thereof or its expression product wherein the presence of said Taq1 allelic form of IL-12 p40 genetic sequence or derivative thereof or its expression product is indicative of the presence of the disease condition or the propensity to develop said disease condition.

[0015] Yet still another aspect of the present invention provides a method of determining the presence of an autoimmune disease condition or a predisposition for the development of an autoimmune disease condition in a mammalian animal said method comprising screening for the presence of an allelic form of IL-12 p40 genetic sequence or derivative thereof or its expression product wherein the presence of said allelic form of IL-12 p40 genetic sequence or a derivative thereof or its expression product is indicative of the presence of said autoimmune disease condition or the propensity to develop said autoimmune disease condition.

[0016] A further aspect of the present invention provides a method of determining the presence of IDDM or a predisposition for the development of IDDM in a mammalian animal said method comprising screening for the presence of the Taq1⁻ allelic form of IL-12 p40 genetic sequence or derivative thereof or its expression product wherein the presence of said Taq1⁻ allelic form of IL-12 p40 genetic sequence or derivative thereof or its expression product is indicative of the presence of said IDDM or the propensity to develop said IDDM.

[0017] Another further aspect of the present invention provides a method of determining the presence of a disease condition or a predisposition for the development of a disease condition in a mammalian animal said method comprising screening for the presence of a form of IL-12 p40 genetic sequence or derivative thereof or its expression product wherein said IL-12 p40 genetic sequence or derivative thereof is linked to another gene.

[0018] Yet another further aspect of the present invention provides a method of determining IDDM or a predisposition for the development of IDDM in a mammalian animal said method comprising screening for the presence of an allelic form of IL-12 p40 genetic sequence or derivative thereof or its expression product wherein said allelic form of IL-12 p40 genetic sequence or derivative thereof is linked to another gene.

[0019] Still another further aspect of the present invention provides a method of determining the presence of IDDM or a predisposition for the development of IDDM in a mammalian animal said method comprising screening for the presence of the Taq1⁻ allelic form of IL-12 p40 genetic sequence or derivative thereof or its expression product wherein said Taq1⁻allelic form of IL-12 p40 genetic sequence or derivative thereof is linked to another gene.

[0020] Yet still another further aspect of the present invention there is provided a method of determining resistance to a disease condition in a mammal said method comprising screening for the presence of a form of IL-12 p40 genetic sequence or derivative thereof or its expression product wherein the presence of said form of IL-12 p40 genetic sequence or derivative thereof or its expression product is indicative of resistance to developing said disease condition.

[0021] Still yet another further aspect of the present invention provides a method of determining resistance to a disease condition characterised, exacerbated or otherwise associated with Th1/Th2 dysregulation in a mammalian animal said method comprising screening for the presence of an allelic form of IL-12 p40 genetic sequence or derivative thereof or its expression product wherein the presence of said allelic form of IL-12 p40 genetic sequence or derivative thereof is indicative of a resistance to developing said disease condition.

[0022] Another aspect of the present invention provides a method of determining resistance to IDDM in a mammalian animal said method comprising screening for the presence of the Taq1⁺ allelic form of IL-12 p40 genetic sequence or derivative thereof or its expression product wherein the presence of said Taq1⁺ allelic form of IL-12 p40 genetic sequence or derivative thereof or its expression product is indicative of a resistance to developing IDDM.

[0023] Yet another aspect of the present invention there is provided a method of determining resistance to a disease condition in a mammalian animal said method comprising screening for the presence of a form of IL-12 p40 genetic sequence or derivative thereof or its expression product wherein said IL-12 p40 genetic sequence or derivative thereof is linked to another gene.

[0024] Still another aspect of the present invention provides a method of determining resistance to IDDM in a mammalian animal said method comprising screening for the presence of the Taq1⁺ allelic form of IL-12 p40 genetic sequence or derivative thereof or its expression product wherein said Taq1⁺ allelic form of IL-12 p40 genetic sequence or derivative thereof is linked to another gene.

[0025] The present invention should also be understood to extend to methods of detecting novel IL12 p40 polymorphisms based on the use of familial gene transfer linkage studies.

[0026] A kit for determining the presence of a disease condition or a predisposition to the development of a disease condition in a mammalian animal said kit comprising a means of detecting the presence or absence of a form of IL-12p40 genetic sequence or derivative thereof or its expression product.

[0027] Another aspect of the present invention provides a kit for determining the presence of a disease condition or a predisposition to the development of a disease condition in a mammalian animal said kit comprising in compartmental form a first compartment adapted to contain an agent for detecting the form of IL-12 p40 genetic sequence or derivative thereof or its expression product and a second compartment adapted to contain reagents useful for facilitating the detection by the agent in the first compartment. Further compartments may also be included, for example, to receive a biological sample. The agent may be an oligonucleotide or antibody or other suitable detecting molecule.

[0028] Yet another aspect of the present invention provides a kit for determining resistance to a disease condition in a mammalian animal said kit comprising in compartmental form a first compartment adapted to contain an agent for detecting the form of IL-12 p40 genetic sequence or derivative thereof or its expression product and a second compartment adapted to contain reagents useful for facilitating the detection by the agent in the first compartment. Further compartments may also be included, for example, to receive a biological sample. The agent may be an oligonucleotide or antibody or other suitable detecting molecule.

[0029] The present invention further contemplates a method of treatment and/or prophylaxis of the disease conditions herein defined said method comprising administering to a mammal an effective amount of a form of IL-12 p40 genetic sequence or derivative, agonist or antagonist thereof or a molecule which regulates the functioning of said IL-12 p40 genetic sequence or its expression product or derivative, antagonist or agonist thereof wherein said IL-12 p40 or regulatory molecule thereof promotes resistance to said disease condition.

BRIEF DESCRIPTION OF THE DRAWINGS

[0030]FIG. 1 is a schematic representation of a high resolution map of the IL12p40 locus.

[0031] A. Placement of IL-12p40 on the radiation hybrid map of chromosome 5q33 relative to the genes GABRA1 (Johnson et al., 1992) and GABRA6 (Hicks et al., 1994) and microsatellite markers (Weissenbach et al., 1992). Oligonucleotides were designed to amplify sequences from the 3′ untranslated region of the human IL-12p40 gene but not from hamster genomic DNA. Radiation hybrids from the Genebridge 4 series (Research Genetics, AL) was tested for human IL-12p40. Additional primers, including GABR41AA (Johnson et al., 1992) and D5S403, D5S410 and D5S412 (Weissenbach et al., 1992) were also tested. The results were used to search against the Whitehead Institute database (http://wwwgenome.wi.mit.edu/cgi-bin/contig/rhmapper.pl) using a LOD=15 for linkage to the framework map.

[0032] B. Detailed restriction maps of the PAC and BAC clones containing IL-12p40. A PAC containing IL12p40 was isolated by screening pools from the human PAC library produced by (Ioannou et al., 1994). The direction of transcription of the gene is shown by the arrow. The marker 93/SP6 was obtained from the end sequence of PAC93-1, and used to screen a BAC library. The resulting clone, BAC 626-19, had an 165 kb insert containing the entire PAC93-1 insert (130 kb) with an additional 2.5- and 30-kb at its SP6 and T7 ends, respectively. Restriction enzyme maps were prepared after digestion with NotI, SalI, SacII and MluI, followed by resolution by pulsed field gel electrophoresis, and hybridization with oligonucleotides complementary to the vector ends (T7 or SP6) or to the promoter or 3UTR of IL-12p40.

[0033] C. Genomic organisation of the human IL-12p40 gene By comparing the complete genomic sequence with published cDNA sequences, the position of exons 1-8 and introns was deduced. Open boxes=coding exons; first and last exons are non-coding. Size of introns is indicated below the line. Start and stop codons are indicated. The asterisk indicates the presence of a mRNA degradation motif (Zubiaga et al., 1995). Arrows indicate approximate positions of confirmed polymorphisms (see Tables 8, 9 and 10).

[0034]FIG. 2 is a schematic representation of the Complete genomic sequence of the IL-12p40 gene (<400>130). The sequence starts 2,397 nucleotides upstream of the TATA box and overlaps the previously published partial promoter sequence. The eight exon sequences (underlined) were determined by comparison with the IL-12p40 cDNA sequences. The translation initiation (ATG) and termination (TAG) codons are double underlined. The 9 base AU-rich element (ARE) consensus sequence is indicated by thick underlining.

[0035]FIG. 3 is a graphical representation of linkage of TID to chromosome 5q. Families with at least two affected sibs were genotyped at markers extending over 33 cM of chromosome 5q. Multipoint linkage analysis was undertaken using the MAPMAKER/Sibs software program (Kruglyak et al., 1995). Output shows maximized lod scores (Holmans P., 1993) for all 249 sibpairs from 187 multiplex families (dashed line). MLS scores were also determined for sibpairs who were either identical (HLA IBD) or mismatched (HLA MIS). Dotted line indicates MLS=2.3, which may be taken as significant evidence for linkage in a single test for linkage (Holians P., 1993). Markers were microsatellite repeats (Weissenbach et al., 1992) including the highly polymorphic repeat within the gene GABRA1.

[0036]FIG. 4 is a diagramatic representation of TDT of IL12B markers placed on the physical map of 5q33-34.

[0037] A. Physical map of YAC (left) and BAC (right) clones containing IL12B. The transcriptional orientation is shown with respect to the centromere. The location of the D5S2937 TAA repeat (box) and the SP6 end (circle) of the PAC clone 93.1 is shown in relation to the genetic markers within the promoter, intron 4 and 3′ UTR of IL12B. Additional anonymous markers on the YAC map are indicated as crosses; the ADRA1b is located telomeric to, and is in the same transcriptional orientation as, IL12B. YAC's shown are (from left): 917b7, 910b3 and 756f1. Further YAC and PAC details were described previously (Huang et al., in press). Restriction sites were determined for Notl (Not), Sacl (Sac), M7ul (Mlu) and Sall (Sal).

[0038] B. TDT of IL12B markers. Results from families in which sibs show linkage to IL12B (that is, “IBD 2”) or not (“IBD 1/0”) are shown as the negative log of the P value returned from the TDT. IBD status was assessed by genotypes at the highly polymorphic nearby GABRA4 locus and also at flanking markers. Transmission ratio of the 3′ UTR alleles in IBD 2 families was 76:33 and in IBD 1/0 families was 95:89; of the intron 4 alleles was 61:22 and 76:63; and of the promoter alleles was 44:61 and 132:130, respectively.

[0039]FIG. 5 is a diagramatic representation of allele-dependent expression of IL12B.

[0040] A. Total RNA was isolated from 1/1 and 2/2 EBV-transformed cell lines and northern analysis was performed with human IL12B and GAPDH cDNA probes.

[0041] B. The levels of IL12B MRNA in each cell line relative to GAPDH was determined by densitometry. Bars show mean±s.e. for three separate experiments.

[0042]FIG. 6 is a schematic representation of the sequence determination and comparison of IL12p40 promoter alleles in humans.

[0043] A. The sequence of the region containing the polymorphism 5′ of the IL-12p40 gene is shown (<400>131). This sequence was determined from a PAC clone we isolated. Underlined=match with published seq (GENBANK HSU89323, Ma et al); bold=oligos used to amplify polymorphism. NB; we have designed another REV oligo to allow for generation of a smaller PCR product. (The first rev oligo is indicated by italics).

[0044] B. Alignment of human alleles 1 (<400>132) and 2 (<400>133) showing the complex change involving the insertion of 5 bases and the deletion of a G resulting in a nett gain of 4 bases compared to the shorter allele 2. No other differences were found in a total of 2 kb sequenced upstream of the IL-12p40 gene.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0045] The present invention is predicated, in part, on the identification of allelic variants of an IL 12 subunit and more particularly p40 subunit of IL-12 and the surprising observation that a correlation exists between the expression of a particular genetic variant and the onset of an autoimmune disease condition such as, but not limited to, IDDM. Although not intending to limit the invention to any one theory or mode of action, it is proposed that genetic variation in the IL-12 p40 gene modulates the expression levels of the RNA thereby modulating the levels of the IL-12 protein and thereby biasing the Th cell response either towards a Th2 type response or a Th1 type response. This proposed mechanism of action now provides a means for the development of a method of screening individuals to determine a predisposition to developing diseases involving the dysregulation of the Th1/Th2 response and or resistance thereto a means for the rational design of therapeutic or prophylactic regimes and/or molecules for modulation of the Th1/Th2 response.

[0046] Accordingly, one aspect of the present invention provides a method of determining the presence of a disease condition or a predisposition for the development of a disease condition in a mammalian animal said method comprising screening for the presence of a form of IL-12 p40 genetic sequence or derivative thereof or its expression product wherein the presence of said form of IL-12 p40 genetic sequence or derivative thereof or its expression product is indicative of the presence of the disease condition or the propensity to develop said disease condition.

[0047] More particularly the present invention provides a method of determining the presence of a disease condition characterised, exacerbated or otherwise associated with Th1/Th2 dysregulation or a predisposition for the development of a disease condition characterised, exacerbated or other associated with Th1/Th2 dysregulation in a mammalian animal said method comprising screening for the presence of a form of IL-12 p40 genetic sequence or derivatives thereof or its expression product wherein the presence of said form of IL-12 p40 genetic sequence or derivative thereof or its expression product is indicative of the presence of the disease condition or the propensity to develop said disease condition.

[0048] The term “mammalian animal” includes humans, primates, livestock animals (e.g. horses, cattle, sheep, pigs, donkeys) laboratory test animals (e.g. mice, rats, rabbits, guinea pigs) companion animals (e.g. dogs, cats) and captive wild animals (e.g. kangaroos, deer, foxes). Preferably, the mammal is a human or a laboratory test animal. Even more preferably the mammal is a human.

[0049] IL-12 is a heterodimeric glycoprotein composed of unrelated subunits of 35 kDa (p35) and 40 kDa (p40). Accordingly, reference to “IL-12 p40 genetic sequence” should be understood as a reference to all forms of DNA- and RNA encoding (i) all or part of the p40 subunit of IL-12 and derivatives thereof or (ii) all or part of a regulatory sequence (such as a promoter sequence) which directly or indirectly regulates the expression of the IL-12 p40 subunit and is located at a position other than between the IL-12 p40 genomic DNA transcription initiation and termination sites and derivatives thereof.

[0050] This definition includes, but is not limited to, all forms of the IL-12 p40 genomic DNA sequence, for example:

[0051] (i) allelic variants such as the Taq1⁺ (<400>1) and Taq1⁻ (<400>2), allelic forms which are defined on the basis of the presence of a deoxycytosine or deoxyadenine nucleotide, respectively, at position 235 of <400>1 and <400>2. <400>1 and <400>2 are partial IL-12 p40 cDNA sequences and depict the 3′ end of the IL-12 p40 cDNA. Position 235 occurs in the 3′ untranslated region of the cDNA sequence.

[0052] (ii) allelic variants such as those characterised by promotor region polymorphisms (<400>3, <400>4, <400>5, <400>6, <400>7, <400>8, <400>132, <400>133).

[0053] (iii) allelic variants such as those characterised by polymorphisms in exon 6 (<400>9, <400>10), exon 7 (<400>11, <400>12) or exon 8 (<400>13, <400>14).

[0054] (iv) allelic variants such as those characterised by polymorphisms in intron 1 (<400>41<400>48), intron 2 (<400>49-<400>52), intron 4 (<400>55, <400>58) and intron 7 (<400>59, <400>60).

[0055] (v) allelic variants characterised by the presence of any one or more of the polymorphisms detailed in (i)-(iv) all forms of the RNA transcribed from said IL-12 p40 genomic DNA sequence (for example the primary RNA transcript, mRNA or splice variants of the RNA transcript) and the cDNA generated from RNA transcribed from said IL-12 p40 genetic sequence.

[0056] Preferably said IL-12 p⁴0 is the Taq1⁺ and/or Taq1⁻ allelic form.

[0057] According to this preferred embodiment the present invention provides a method of determining the presence of a disease condition characterised, exacerbated or otherwise associated with Th1/Th2 dysregulation or a predisposition for the development of a disease condition characterised, exacerbated or otherwise associated with Th1/Th2 dysregulation in a mammalian animal said method comprising screening for the presence of an allelic form of IL-12 p40 genetic sequence or derivative thereof or its expression product wherein the presence of said allelic form of IL-12 p40 genetic sequence or derivative thereof or its expression product is indicative of a propensity to develop said disease condition.

[0058] More preferably the present invention provides a method of determining the presence of a disease condition characterised, exacerbated or otherwise associated with Th1/Th2 dysregulation or a predisposition for the development of a disease condition characterised, exacerbated or otherwise associated with Th1/Th2 dysregulation in a mammalian animal said method comprising screening for the presence of the Taq1⁺ allelic form of IL-12 p40 genetic sequence or derivative thereof or its expression product wherein the presence of said Taq1⁺ allelic form of IL-12 p40 genetic sequence or derivative thereof or its expression product is indicative of a propensity to develop said disease condition.

[0059] Even more preferably said IL-12 p40 Taq1⁺ allelic form comprises the nucleotide sequence substantially as set forth in<400>1.

[0060] In another preferred embodiment the present invention provides a method of determining the presence of a disease condition characterised, exacerbated or otherwise associated with Th1/Th2 dysregulation or a predisposition for the development of a disease condition characterised, exacerbated or otherwise associated with Th1/Th2 dysregulation in a mammalian animal said method comprising screening for the presence of the Taq1⁻ allelic form of IL-12 p40 genetic sequence or derivative thereof or its expression product wherein the presence of said Taq1⁻ allelic form of IL-12 p40 genetic sequence or derivative thereof or its expression product is indicative of a propensity to develop said disease condition.

[0061] Even more preferably said IL-12 p40 Taq1⁻ allelic form comprises the nucleic acid sequence substantially as set forth in<400>2.

[0062] It should be understood that the presence of the Taq1⁺ or Taq1⁻ polymorphism may be indicative of a number of disease conditions characterised by Th1/Th2 dysregulation. In one embodiment, to the extent that the disease condition is IDDM, Taq1⁻ expression in an individual is indicative of a propensity to develop IDDM while Taq+expression in an individual is indicative of resistance to the development of IDDM.

[0063] Reference to “expression product” should be understood as a reference to the peptide, polypeptide or protein resulting from the translation of IL-12 p40 RNA sequences or transcription and translation of IL-12 p40 DNA sequences as hereinbefore defined.

[0064] Reference to a disease condition “characterised, exacerbated or otherwise associated with Th1/Th2 dysregulation” should be understood as a reference to a disease condition in which at least some of the pathology associated with said disease condition is either directly or indirectly due to the activation of a particular subpopulation of Th cells. For example, IDDM is characterised by a Th1 type response. Preferably, said disease condition is an autoimmune disease condition.

[0065] Accordingly, another aspect of the present invention provides a method of determining the presence of an autoimmune disease condition or a predisposition for the development of an autoimmune disease condition in a mammalian animal said method comprising screening for the presence of an allelic form of IL-12 p40 genetic sequence or derivative thereof or its expression product wherein the presence of said allelic form of IL-12 p40 genetic sequence or a derivative thereof or its expression product is indicative of the presence of said autoimmune disease or the propensity to develop said autoimmune disease condition.

[0066] Preferably, said autoimmune disease condition is an autoimmune disease condition characterised, exacerbated or otherwise associated with Th1/Th2 dysregulation.

[0067] Even more preferably, said allelic form of IL-12 p40 is the Taq1⁺ or Taq1⁻ form.

[0068] Without limiting the present invention to any one theory or mode of action, disease conditions characterised by Th1/Th2 dysregulation are thought to be mediated by an imbalance in the Th response in that it is incorrectly skewed towards either a Th1 or Th2 response. The skewing of Th cells towards either a Th1 or a Th2 response is now envisaged as at least partly regulated by genetic variation in the IL-12 p40 gene which acts to modulate the expression levels of the IL-12 p40 polypeptide. Analysis of the frequency of Taq1⁺ and Taq1⁻ IL-12 p40 alleles in subjects who exhibit symptoms of IDDM indicates that expression of a Taq1⁻ allele is indicative of susceptibility to IDDM while expression of a Taq1⁺ allele is indicative of resistance to IDDM.

[0069] According to this most preferred embodiment, the present invention provides a method of determining the presence of IDDM or a predisposition for the development of IDDM in a mammalian animal said method comprising screening for the presence of the Taq1⁻ allelic form of IL-12 p40 genetic sequence or derivative thereof or its expression product wherein the presence of said Taq1⁻ allelic form of 1L-12 p40 genetic sequence or derivative thereof or its expression product is indicative of the presence of said IDDM or the propensity to develop said IDDM.

[0070] The present invention should be understood to extend to methods of determining the presence of a disease condition characterised, exacerbated or otherwise associated with Th1/Th2 dysregulation, or a predisposition thereof, by screening for the combination of a Taq1⁺/Taq1⁻ polymorphism together with any other polymorphism expressed by an individual.

[0071] Still without limiting the invention to any one theory or mode of action, transmission disequilibrium studies have further indicated that in certain disease conditions characterised by Th1/Th2 dysregulation the Taq1⁺ and Taq1⁻ allelic forms of IL-12 p40 are indicative of a predisposition to developing said disease when they have been transmitted to the affected mammal in a form where they are linked to another gene. The method of the present invention is exemplified herein utilising the genetic marker GABRAL which occurs in two allelic forms—A and B. Expression of the Taq1⁻/GABRA1-A haplotype where the two genes are linked is indicative of IDDM susceptibility while expression of the Taq1⁻/GABRA1-A haplotype where the two genes are unlinked is not indicative of IDDM susceptibility. Conversely, transmission of the Taq1⁺/GABRA-A haplotype in a linked form is indicative of IDDM resistance.

[0072] Accordingly, a related aspect of the present invention provides a method of determining the presence of a disease condition or a predisposition for the development of a disease condition in a mammalian animal said method comprising screening for the presence of a form of IL-12 p40 genetic sequence or derivative thereof or its expression product wherein said IL-12 p40 genetic sequence or derivative thereof is linked to another gene.

[0073] Reference to genes being “linked” is a reference to any two or more genes which do not assort independently at meiosis. Determining the linkage of two genes can be achieved by any one of a number of methods including for example screening one or more parents of said mammal to determine the pattern of gene transmission and thereby the degree of linkage between the IL-12 p40 gene or derivative thereof and another gene. Alternatively, said linkage can be determined by screening one or more parents and comparing with a proband.

[0074] Preferably said form of IL-12 p40 is an allelic form of IL-12 p40.

[0075] In a most preferred embodiment, said disease condition is an autoimmune disease condition and most preferably IDDM.

[0076] According to this most preferred embodiment the present invention provides a method of determining IDDM or a predisposition for the development of IDDM in a mammalian animal said method comprising screening for the presence of an allelic form of IL-12 p40 genetic sequence or derivative thereof or its expression product wherein said allelic form of IL-12 p40 genetic sequence or derivative thereof is linked to another gene.

[0077] Most preferably the present invention provides a method of determining the presence of IDDM or a predisposition for the development of IDDM in a mammalian animal said method comprising screening for the presence of the Taq1⁻ allelic form of IL-12 p40 genetic sequence or derivative thereof or its expression product wherein said Taq1⁻ allelic form of IL-12 p40 genetic sequence or derivative thereof is linked to another gene.

[0078] Preferably, the gene to which said IL-12 p40 genetic sequence is linked is an informative genetic marker. By “informative” it is meant a genetic marker which when used in conjunction with said IL-12 p40 genetic sequence improves or otherwise indicates involvement of said IL-12 p40 genetic sequence in the subject disease or other condition. Preferably, said informative genetic marker is a GABRA allele.

[0079] Even more preferably, said other gene is the GABRA1-A allele genetic marker.

[0080] The expression of a particular form of IL-12 p40 is also indicative of a mammal's resistance to developing a disease condition characterised by Th1/Th2 dysregulation.

[0081] Accordingly, in another aspect of the present invention there is provided a method of determining resistance to a disease condition in a mammal said method comprising screening for the presence of a form of IL-12 p40 genetic sequence or derivative thereof or its expression product wherein the presence of said form of IL-12 p40 genetic sequence or derivative thereof or its expression product is indicative of resistance to developing said disease condition.

[0082] Preferably, said disease condition is characterised, exacerbated or otherwise associated with Th1/T2 dysregulation.

[0083] More preferably said form of IL-12.p40 genetic sequence is an allelic form of IL-12 p40 genetic sequence.

[0084] According to this most preferred embodiment the present invention provides a method of determining resistance to a disease condition characterised, exacerbated or otherwise associated with Th1/Th2 dysregulation in a mammalian animal said method comprising screening for the presence of an allelic form of IL-12 p40 genetic sequence or derivative thereof or its expression product wherein the presence of said allelic form of IL-12 p40 genetic sequence or derivative thereof is indicative of a resistance to developing said disease condition.

[0085] Most preferably said allelic form of IL-12 p40 is the Taq1⁺ or Taq1⁻ allelic form.

[0086] In a most preferred embodiment said disease condition is an autoimmune disease condition and even more preferably IDDM.

[0087] According to this most preferred embodiment the present invention provides a method of determining resistance to IDDM in a mammalian animal said method comprising screening for the presence of the Taq1⁺ allelic form of IL-12 p40 genetic sequence or derivative thereof or its expression product wherein the presence of said Taq1⁺ allelic form of IL-12 p40 genetic sequence or derivative thereof or its expression product is indicative of a resistance to developing IDDM.

[0088] In another related aspect of the present invention there is provided a method of determining resistance to a disease condition in a mammalian animal said method comprising screening for the presence of a form of IL-12 p40 genetic sequence or derivative thereof or its expression product wherein said IL-12 p40 genetic sequence or derivative thereof is linked to another gene.

[0089] Preferably, said disease condition is characterised, exacerbated or otherwise associated with Th1[Fh2 dysregulation. Even more preferably said disease condition is an autoimmune disease condition and most preferably IDDM.

[0090] Still more preferably said IL-12 p40 is the Taq1⁺ allelic form.

[0091] According to this most preferred embodiment the present invention provides a method of determining resistance to IDDM in a mammalian animal said method comprising screening for the presence of the Taq1⁺ allelic form of IL-12 p40 genetic sequence or derivative thereof or its expression product wherein said Taq1⁺ allelic form of IL-12 p40 genetic sequence or derivative thereof is linked to another gene.

[0092] Most preferably said other gene is GABRA1-A allele genetic marker.

[0093] Reference to detecting “resistance” should be understood to generally refer to detecting a reduction in the pathology associated with an existing disease condition, preventing, delaying or minimising the onset of pathology associated with the onset of said disease condition, or preventing the onset of said disease condition.

[0094] The present invention should also be understood to extend to methods of detecting novel IL-12 p40 polymorphisms based on the use of familial gene transfer linkage studies. Further sequence polymorphisms may exist in the vicinity of the IL-12 p40 gene. Some of these may also be involved in regulating IL12 p40 gene expression and therefore the ability to produce Th1 or Th2 dominated immune response and hence resistance or susceptibility to autoimmune disease. Such polymorphisms may be tested by their co-segregation with the IL-12 p40 Taq− allele to IDDM subjects, or by their non-transmission in linkage with the IL12 p40 Taq+ allele. An example of how such an additional polymorphism may be detected and its utility is provided with reference to the GABRA-A genotype in Table 6. Such additional polymorphisms may be tested in, for example, functional assays by in vitro transfection experiments using appropriate reporter constructs.

[0095] Screening of the forms of IL-12 p40 genetic sequences or derivatives thereof or its expression products may be achieved utilizing any of a number of techniques including PCR analysis and antibody binding assays.

[0096] In one preferred method, the IL-12 p40 gene or transcribed RNA is subjected to PCR or RT-PCR, respectively, using primers homologous to gene sequences located 5′ and 3′ of the Taq1 polymorphism. The oligonucleotide is generally labelled with a reporter molecule capable of giving an identifiable signal such as a radioisotope, chemiluminesce molecule or a fluorescent molecule. A particularly useful reporter molecule is a biotinylated molecule.

[0097] Another useful detection system involves antibodies directed to the various forms of IL-12 p40 genetic sequences, to the Taq1 polymorphism itself or to the expression products of the various IL-12 p40 forms. Detection utilising antibodies may be accomplished immunologically in a number of ways such as by Western Blotting and ELISA procedures. These procedures include both single site and two site or “sandwich” assays of the noncompetitive type, as well as the traditional competitive binding assays. These assays also include direct binding of a labelled antibody to a target.

[0098] Another aspect of the present invention provides a kit for determining the presence of a disease condition or a predisposition to the development of a disease condition in a mammalian animal said kit comprising a means of detecting the presence or absence of a form of IL-12 p40 genetic sequence or derivative thereof or its expression product.

[0099] Without limiting this aspect of the present invention in any way, the subject kit may be designed to detect either the presence of a given allele, or its absence, in an individual. In a preferred embodiment the presence of a specific allele is screened for. The means by which the subject kit detects the form of IL-12 p40 may be any suitable means including, but not limited to, any mass spectrometry technique, gels, DNA or protein chips, DNA probing means, antibody or other immunological reagent.

[0100] In one embodiment the present invention provides a kit for determining the presence of a disease condition or a predisposition to the development of a disease condition in a mammalian animal said kit comprising in compartmental form a first compartment adapted to contain an agent for detecting the form of IL-12 p40 genetic sequence or derivative thereof or its expression product and a second compartment adapted to contain reagents useful for facilitating the detection by the agent in the first compartment. Further compartments may also be included, for example, to receive a biological sample. The agent may be an oligonucleotide or antibody or other suitable detecting molecule.

[0101] In another embodiment the present invention provides a kit for determining resistance to a disease condition in a mammalian animal said kit comprising in compartmental form a first compartment adapted to contain an agent for detecting the form of IL-12 p40 genetic sequence or derivative thereof or its expression product and a second compartment adapted to contain reagents useful for facilitating the detection by the agent in the first compartment. Further compartments may also be included, for example, to receive a biological sample. The agent may be an oligonucleotide or antibody or other suitable detecting molecule.

[0102] The present invention further contemplates a method of treatment and/or prophylaxis of the disease conditions hereinbefore defined said method comprising administering to a mammal an effective amount of a form of IL-12 p40 genetic sequence or derivative, agonist or antagonist thereof or its expression product or derivative, antagonist or agonist thereof wherein said IL-12 p40 promotes resistance to said disease condition. For example, in patients suffering from IDDM or a predisposition to developing IDDM the Taq1⁺ form of the IL-12 p40 gene or transcription or translation product or molecules which regulate Taq1⁺ functioning or expression may be administered. The present invention facilitates modulation of the immune system response both in disease states or in non-disease states where it is nevertheless desirable (for example, to regulate IL-12 levels as part of a vaccination protocol).

[0103] Administration of said IL-12 p40 can be achieved via one of several techniques including, but in no way limited to:

[0104] (i) Introduction of a nucleic acid molecule encoding a particular form of IL-12 p40 or a derivative thereof to modulate the capacity of that cell to synthesize said IL-12 p40.

[0105] (ii) Introduction into a cell of a proteinaceous IL-12 p40 molecule of particular form or derivative thereof.

[0106] The present invention may be used for the screening of individuals, families and populations. In this regard, the inventors have determined that the relationship between Taq1 allele expression and IDDM resistance or susceptibility is particularly evident in individuals who are ethnically of Northern European or United Kingdom origin. Accordingly, in a preferred embodiment the methods of the present invention are directed to screening individuals of this ethnic origin.

[0107] Further features of the present invention are more fully described in the following nonlimiting Examples. It is to be understood, however, that this detailed description is included solely for the purposes of exemplifying the present invention. It should not be understood in any way as a restriction on the broad description of the invention as set out above.

EXAMPLE 1 Detection of IL-12 Taq Polymorphism

[0108] A polymorphism was found in the 3′ UT region of the IL-12 p40 gene. This polymorphism was detected as follows. DNA was obtained from peripheral blood lymphocytes using standard techniques, and used to initiate polymerase chain reaction (PCR) using synthetic oligonucleotides and Taq DNA polymerase (Gibco). The sequences of these oligos were as follows: FORWARD TAGCTCATCTTGGAGCGAAT (<400>134) REVERSE AACATTCCATACATCCTGGC (<400>135)

[0109] Reverse oligo hybridises to the following sequence in 3′ UT region: GCCAGGATGTATGGAATGTT (<400>136)

[0110] Following PCR, aliquots of the reaction products were incubated with Taq1 restriction enzyme (Promega) under conditions suggested by the manufacturer. The samples were then ran on gels (either agarose gels, or acrylamide gels if the primer was first labelled with 32p ATP) to determine the lengths of the DNA fragments. Using the above primers, a product of approximately 0.3 kbp is generated; if the Taq1 site is present, this yields fragments of approximately 0.14 and 0.16 kbp after digestion. Allele 1 is designated as the allele not digested by Taq1; allele 2 contains the Taq1 site (i.e. TCGA).

[0111] Other methods for detecting this polymorphism include use of different oligonucleotides flanking the Taq1 site; use of allele-specific primers to preferentially amplify allele 1 (Taq1⁻ polymorphism) or allele 2 (Taq1⁺ polymorphism) sequences; testing products by hybridisation using allele-specific oligonucleotides; testing products or fragments derived therefrom for differences in mass by appropriate methods, e.g. mass spectrometry.

EXAMPLE 2 Determining the Frequency of Alleles 1 and 2 in Control Subjects

[0112] The frequency of alleles 1 and 2 in controls was determined by typing DNA samples from anonymous donors.

EXAMPLE 3

[0113] IL-12 Allele Expression and IDDM Susceptibility

[0114] The role of IL-12 p40 alleles in insulin-dependent diabetes mellitus (IDDM) was tested by determining whether either allele was preferentially transmitted to affected offspring.

[0115] These alleles were typed as described in Example 2. Transmission or nontransmission of these alleles from appropriate parents to affected offspring was determined using the Transmission Disequilibrium test (TDT) in the Genetic Analysis System programs (A. Young, GAS Manual User Guide v1.2 (Oxford University, 1995). Results for families are shown in table 1. TABLE 1 Transmission of IL-12 p40 alleles in IDDM families Allele Both parents Trans Not Prob (binom) 1 159 110 0.0017 2 110 159

[0116] These results show that allele 1 is preferentially transmitted and allele 2 is preferentially not transmitted to IDDM offspring.

EXAMPLE 4

[0117] Confirmation of the use of the Taq allele as an indicator of susceptibility to IDDM was obtained from an independent sample of 238 families recruited through the Royal Melbourne and Royal Children's Hospitals. TABLE 2 Allele Trans Not Trans p 1 58 32 0.004 2 32 58 1

[0118] These data indicate that allele 1 is preferentially transmitted (i.e. confers susceptibility or is in linkage disequilibrium with the polymorphism that confers susceptibility) and that allele 2 is preferentially not transmitted (i.e. confers resistance).

[0119] When these data are analysed with respect to ethnic origin, the following is found: TABLE 3 North European ethnicity Allele Trans Not Trans p 1 49 18 9.7e−05 +++ 2 18 49 1

[0120] TABLE 4 Non-North European ethnicity Allele Trans Not Trans p 1 9 14 0.8 2 14 9 0.2

[0121] This suggests that this gene is particularly indicative of fDDM in individuals who ethnically originate from the UK and northern Europe.

[0122] Pooling the Example 3 data together with the Example 4 data indicates that the total p value in all families (i.e. unselected for linkage to GABRA) is 6×10⁻⁶.

EXAMPLE 5 Linked IL-12 Allele Transmission and IDDM Susceptibility

[0123] A linked genetic marker in the GABRA-A receptor α1-subunit gene (GABRA1) was also typed. The GABRAL alleles were detected as described by Johnson, K J, et al Genomics 14:745-8. These alleles were subsequently simplified for the transmission disequilibrium analysis as they were found to fall into two distinct groups: the six highest MW alleles were designated as “A” and the three lowest were designated as “B”.

[0124] DNA was analysed from families in which at least two children had IDDM. Linkage was assessed by evaluating whether the affected sibs had inherited GABRA1 and linked genes identical-by-descent (IBD) i.e. whether they had inherited the same maternal and the same paternal alleles at GABRA1 and/or at other flanking markers. IBD status for a particular chromosomal region suggests that affected sibs share gene(s) which influence disease susceptibility; such sibs are said to show genetic linkage to the markers shared IBD). Two groups could thus be defined: those who were IBD at the IL-12 p40/GABRA region, and those who were not IBD. Transmission of alleles 1 and 2 were evaluated in sibs showing linkage to GABRA1/IL-12 p40. Families showing no linkage to IL-12 p40 did not show preferential transmission of either allele. Families whose affected sibs showed linkage to IL-12 p40/GABRA1 showed preferential transmission of allele 1, and preferential non-transmission of the other allele. This indicated that these alleles were associated with IDDM susceptibility and resistance, respectively (Table 5). TABLE 5 Transmission of IL-12 p40 alleles in sibs showing linkage to IL-12 p40. Allele Both Parents Trans Not Prob (binom) 1 102 61 0.00082 2 61 102

[0125] By considering the IL-12 alleles and the linked GABRA1 marker, four haplotypes were defined, as follows. Haplotype 1A, IL-12 p40 allele 1, GABRA1 A; haplotype 1B, IL-12 p40 allele 1, GABRAL B; haplotype 2A, IL-12 p40 allele 2, GABRA1 A; haplotype 2B, IL-12 p40 allele 2, GABRA1 B. Transmission or nontransmission of these haplotypes from appropriate parents to affected offspring was determined using the Transmission Disequilibrium test (IDT) in the Genetic Analysis System programs (A. Young, GAS Manual User Guide v1.2 (Oxford University, 1995).

[0126] Families showing no linkage to IL-12 p40 did not show preferential transmission of any haplotype. Families whose affected sibs showed linkage to IL-12 p40/GABRA1 (suggesting that IL-12 p40 may be contributing to their development of IDDM) showed preferential transmission of one haplotype, and preferential non-transmission of another haplotype. This indicated that these haplotypes were associated with IDDM susceptibility and resistance, respectively. (Table 6). Two other haplotypes showed no deviation in transmission, suggesting that they were neutral in conferring susceptibility. TABLE 6 Transmission Disequilibrium Test of IL-12 haplotypes in IDDM. Linkage Status Haplotype Trans Not Trans P Unlinked 1A 84 80 — 1B 74 67 — 2A 22 27 — 2B 25 29 — Linked 1A 94 52 0.00032  1B 62 66 — 2A 8 34 0.000006 2B 24 36 —

EXAMPLE 6 Complete Primary Structure, Chromosomal Localisation and Definition of Polymorphisms of the Gene Encoding the Human IL-12p40 Subunit

[0127] High Resolution Mapping

[0128] Although IL-12p40 had been mapped to chromosome 5q31-33 (Wairington et al., 1994), its position relative to microsatellite markers used in genetic studies has not been reported. Therefore, to localize IL-12p40 relative to other genes (eg GABRA1 (Johnson et al., 1992) and GABRA6 (Hicks et al., 1994)) and genetic markers D5S403, D5S10 and D5S412 9 in this region, radiation hybrid mapping was used (Boehnke et al., 1991). Comparison with previously mapped markers confirmed the assignment of IL-12p40 to distal chromosome 5q FIG. 1A). The optimal location for this gene was 3.3 centiRays (cR) telomeric from the microsatellite marker D5S412, and 3 cR centromeric from the anonymous DNA sequence, WI-9929 and a further 2.2 cR from D5S403 (FIG. 1A). These results integrating the genetic (Weissenbach et al., 1992) and physical maps of distal chromosome 5q will be useful for further genetic studies examining potential roles for IL-12p40 in disease. An inspection of the map of distal human chromosome 5 does not reveal any known diseases mapping to this region which could be attributable to variants in IL-12p40.

[0129] A phage P1-derived artificial chromosome (PAC) clone was isolated from the human PAC library produced by (Ioannou et al., 1994) with primers designed to amplify a segment from the 3′ untranslated region of IL12p40. The PAC clone 93-1 had an insert size of 130 kb. The sequence from the SP6 end of this clone was used to design primers to isolate an overlapping clone from a bacterial artificial chromosome (BAC) library (Osoegawa et al., 1998). A high resolution map of these clones is shown in FIG. 1B. Characterisation of these clones showed that they both contained the complete gene which also was arranged 3′->5′ with respect to the centromere. The MluI site within the IL-12p40 promoter was located 90 kb from the SP6 end of the PAC clone (FIG. 1B).

[0130] Determination of IL-12p40 Genomic Sequence

[0131] Only part of the promoter and the exon 1 genomic sequences of human IL-12p40 have been determined previously (Ma et al., 1996). In order to complete the sequence of the human IL-12p40 gene, the PAC clone, 93-1, was used as a template. DNA sequencing was performed using a walking strategy with fluorochrome-labeled dideoxynucleotide terminators, followed by automated analysis. This strategy was used because the priming oligonucleotides could also be used to generate PCR products for polymorphism testing.

[0132] A total of over 18 kb of sequence was determined and is deposited with Genbank (FIG. 2 provides the complete genomic sequence of the IL-12p40 gene). By alignment of this genomic sequence with the previously published cDNA sequences (Gubler et al., 1991; Wolf et al., 1991) the exact location and sequences of the exons were defined. Sequences at the exon-intron boundaries are reported in Table 7. The organization of the IL-12p40 gene is shown schematically in FIG. 1C. An unusual feature of the gene is that it has untranslated exons at both its 5′ and 3′ ends. Translation from its corresponding mRNA would be initiated at the first codon in exon 2 and would terminate at the last codon of exon 7.

[0133] Comparison of Genomic and cDNA Sequences

[0134] Sequence differences were observed between the sequence of the PAC clone that was determined and the previously reported IL-12p40 sequences, as shown in Table 8. These sequence differences could either represent genetic polymorphisms or arise from sequencing errors. In order to test whether the differences between the PAC sequence and the cDNA sequences were representative of alleles of the IL-12p40 gene, primers were designed to amplify the relevant regions of the gene from genomic DNA of different individuals (anonymous donors of European descent). PCR products were tested for the presence of genetic variants by either restriction enzyme digestion (where appropriate) or by direct sequencing. In this way, the A->C change in the 3UIR, resulting in creation of a TaqI site, was defined as a true genetic variant. In contrast, the C->G change resulting in the K->N amino acid substitution (exemplified by sequence HUMNKSFP40 (Wolf et al., 1991)) could not be found in DNA representing 224 chromosomes, including 97 which had the same IL12p40 allele as HUMNKSFP40, as defined by the presence of the 3UTR TaqI (not shown). Similarly, neither the exon 7 difference nor the promoter differences between the PAC and the published sequences could be confirmed.

[0135] Further Search for polymorphisms in the IL-12 p40 Gene

[0136] DNA from different individuals representative of the TaqI− and TaqI+ alleles was tested for further differences in and around the IL-12p40 gene. Polymorphisms were sought by PCR amplification followed by SSCP, restriction enzyme digestion or direct sequencing. Variants found by SSCP were confirmed by subsequent sequencing (or other methods as appropriate) of samples from a number of unrelated individuals. The results are summarized in Tables 9 and 10. Our major interest was in finding whether commonly occurring IL-12p40 polymorphisms exist as these may be useful for testing in various disease situations. It should be noted that the possibility of other, rarer, IL12p40 variants was not tested and is not excluded.

[0137] Despite extensive searching, no coding region sequence differences were found. Simple sequence repeat polymorphisms were discovered in introns 2 and 4. However, these had limited heterogeneity, with only two and three alleles found for each, respectively. A number of apparent single nucleotide substitutions were found. All the polymorphisms listed in Table 9 and 10 were confirmed by sequencing. Some polymorphisms were examined further in a large sample of unrelated individuals of diverse European descent. In particular, the 3′UTR alleles were found to be in Hardy-Weinberg equilibrium, with the TaqI− allele having a frequency of 0.82. The TA repeat polymorphism in intron 4 showed a similar distribution, also in Hardy-Weinberg equilibrium. The longest allele of this polymorphism is probably in linkage disequilibrium with the 3′UTR TaqI+allele. Even though the sample size was small, there was a suggestion that other polymorphisms may not be in linkage disequilibrium, notably the two single base changes, each A->G, within 14 bp in intron 2 (Table 9, 10). In sequencing this region from 8 individuals, 2 were heterozygous for either form, while of the homozygotes, 5 had the AA haplotype and 1 each the AG and GG haplotypes.

[0138] There was clustering of the DNA sequence variations. Of the twelve polymorphisms found, four were in intron 1, three were in intron 2, and two in intron 4. The changes in introns 1 and 2 appeared in pairs separated by no more than 60 bp. No polymorphisms were found (by SSCP analysis) in introns 5 and 6. In searching for genetic variants in 1L-12p40, no changes were found which would give rise to amino acid changes. An apparent amino acid substitution in comparison with a previously described cDNA sequence could not be found in testing an additional 128 chromosomes. The dearth of any coding sequence changes indicates a high level of conservation between the human subjects tested. Perhaps it was not surprising that no sequence variants were found that resulted in amino acid substitutions, given that IL-12p40 plays a fundamental role in immune regulation (Trinchieri G., 1995). However, this contrasts with the large number of differences displayed between species: there are 116 differences in amino acid sequences between the approximately 335 residues of the mouse and human IL-12p40 proteins (Gubler et al., 1991; Wolf et al., 1991; Tone et al., 1996). Despite the sequence differences, the genomic organization of mouse (Wolf et al., 1991) and human IL-12p40 genes is similar: both have 8 exons and the relative size of the introns is similar in both species. The mouse gene has an untranslated first exon but, unlike the human gene, the last exon does encode part of the final protein product (Wolf et al., 1991).

[0139] The polymorphisms described are useful in genetic studies to determine the role of IL-12p40 in regulation of the immune response in health and disease.

[0140] Method

[0141] Polymorphisms in the IL12p40 gene were sought. DNA fragments covering the entire gene were amplified from a panel of up to 27 unrelated donors and S was performed as follows. Forward and reverse primers shown were selected from the PAC sequence, and used to amplify specific segments of the IL-1 gene. “Standard” PCR conditions were performed incorporating 32 P-dATP: 2′ at 95° C. followed by 35 cycles of 20 s at 95° C., 20 s at 55° C., and 30 s at different extension times are indicated. For SSCP, a portion (1 ml) of the reaction mix was added to 5 ml of loading buffer (95% formamide, 20 mM EDTA, NaOH, 0.05% bromophenol blue and 0.15% xylene cyanol) heated at 90° C. for 1 min. and loaded onto a 4 to 5% polyacrylamide gel (1:45 or 1:90 ratio of N-methylene bisacrylamide to acrylamide). The intron 7 product was digested with EcoRV and HindIII prior to SSCP. Electrophoresis was performed overnight at room temperature. The gel was blotted on filter paper and exposed to autoradiography overnight at −70° C. Fragments which gave variable products were selected for sequencing. Note: the sequencing panel was selected so as to be enriched for individuals homozygous for the exon 8 TaqI allele number of individuals sequenced who were homozygous for the canonical PAC sequence, or for the alternate non-PAC sequence are shown, as is the number heterozygotes.

EXAMPLE 7 Linkage Disequilibrium of Regulatory IL12P40 Alleles with Type I Diabetes

[0142] Results

[0143] To test whether IL12B may be a susceptibility gene in human T1D, 249 sibpairs were typed for markers on chromosome 5q33-34, to which IL12B was mapped (Warrington et al., 1994). Testing multiplex families for markers from this region initially resulted in a modest lod score, suggestive of linkage to a susceptibility gene (FIG. 3). Stratification of sibpairs has proven useful in revealing linkage in multipoint analyses, allowing clear definition of the susceptibility locus IDDM13 (Morahan et al., 1996; Fu et al., 1998; Larsen et al., 1999). Applying stratification to the 5q data revealed a difference between sibpairs sharing HLA haplotypes and those differing at HLA (FIG. 3). The HLA-identical sibpairs showed linkage to this region with a maximized lod greater than 2.3; this susceptibility locus is provisionally amed IDDM18. In contrast, and unlike the case for IDDM13 (Morahan et al., 1996), there was no evidence of linkage in the HLA mismatched sibs. This emphasizes the genetic heterogeneity of TID, such that different subgroups have susceptibility arising from different interactions of HLA and non-HLA genes.

[0144] The linkage analyses indicated that IDDM18 may reside near IL12B. The complete sequence of, and genetic polymorphisms in and around, IL12B have been described (Huang et al., in press). Although there were no common coding region variants, we found useful polymorphisms in the 3′ UTR, intron 4 and the promoter. These polymorphisms were typed and the transmission disequilibrium test (Spielman et al., 1993) TDT was applied. There was significant excess transmission of particular intron 4 and 3′ UTR alleles, but not of alleles defined by the promoter polymorphism (Table 13). (The intron 4 and 3′ UTR alleles are in linkage disequilibrium, so further discussion is limited to the latter). A physical map of >1 Mb surrounding IL12B was constructed (FIG. 4a) and searched for futher downstream polymorphisms; one resulting marker, D5S2937, has 10 alleles, none of which singly or jointly generated significant TDT results (Table 13). These observations were confirmed using the T_(sp) statistic, which adjusts for testing more than one affected subject per family (Martin et al., 1998) (Table 13). Similar results were also obtained testing only one affected sib per family (data not shown).

[0145] To further test the involvement of IL12B polymorphisms in T1D, the families were divided into two groups: one showing linkage to 5q33-34 (which would be expected to shown the influence of the disease allele) and one which did not (and would therefore predominantly include sibs who had TID due to other susceptibility loci). The TDT was applied to each group (FIG. 4b). Evidence for preferential transmission increased in the linked group, whereas there was no significant deviation in transmission of alleles to the unlinked group. (Although this method of selection of sibs for linkage will affect matching of alleles within families, it should not affect genotypes between families, and hence should not affect the overall TDT. In fact, similar results were obtained when the analysis was restricted to the first affected sib (data not shown). The results showed preferential transmission in only those families in which T1D was linked to IL12B, indicating that TID is mediated in part by the IL-12-linked causative polymorphism. There was again preferential transmission of the 3′ UTR polymorphism, but none at the promoter polymorphism only 20 kb upstream (FIGS. 4a,b).

[0146] If the 3′ UTR polymorphism itself contributes to susceptibility, the offspring of homozygous parents should not show linkage, unlike offspring of heterozygous parents (Robinson et al., 1993). Because the frequency of the susceptibility allele is 0.8, the families in which at least one parent is homozygous will be in the majority, helping to explain the low lod scores obtained in the original analysis. Essentially, all the evidence for linkage (MLS=2.632) was maintained in the group with at least one heterozygous parent; there was no evidence for linkage to IL12B promoter alleles in families in which both parents were homozygous at the 3′ UTR (MLS=0.388).

[0147] It was crucial to confirm the above findings of preferential transmission of IL12B 3′ UTR allele 1 to T1D subjects. The Australian IDDM DNA Repository has been established and into which 238 families have been recruited and typed for IL12B-associated polymorphisms. The results confirm those obtained above: preferential transmission of allele 1 of the 3′ UTR polymorphism, and lack of bias in transmission of promoter alleles (Table 14). The Australian IDDM DNA Repository families were also typed at a novel polymorphism, DS2340, located 12 kb downstream of the IL12B 3′ UTR. This marker did not yield significant TDT results (Table 14). Combining the results from both TDT analyses of the IL12B 3′ UTR, the null hypothesis of lack of association of the IL12B 3′ UTR with TID may be rejected (overall P=3.5×10⁷). Significant linkage disequilibrium appears confined to a region of approximately 30 kb in which IL12B is the only known gene.

[0148] The results show that the 3′ UTR allele 1 is preferentially transmitted to T1D subjects, and hence either itself confers susceptibility or is in linkage disequilibrium with the disease-predisposing variant; allele 2 is preferentially non-transmitted, so it may be associated with T1D resistance. As no common change was found in its coding sequences, if IL12B is involved in TID susceptibility then its alleles should show some other functional difference. To address this, EBV-transformed cell lines (which are known to express IL-12; refs. Wolf et al., 1991; Gubler et al., 1991) homozygous for each allele were identified. Expression of IL12B was significantly reduced in the 2/2 genotype cell line relative to the 1/1 line (FIG. 5). The 3′ UTR polymorphism is located over 1 kb from the mRNA degradation element (Zubiaga et al., 1995), so it is unlikely that the observed difference between the cell lines is due to differences in stability. The inference that the 3′ UTR polymorphism may affect gene expression is supported by a similar finding for the rat gene spi2.3 (LeCam et al., 1995). If differences in IL12B expression result in different levels of protein, then individuals with the susceptibility allele should produce more IL12p40. Higher IL-12 levels were found in relatives of T1D probands (Szelachowska et al., 1997). Increased IL-12 may promote Th1 cells, and aggravate autoimmune destruction of β-cells, causing T1D (as in NOD mice (Katz et al., 1995; Trembleau et al., 1995)). In contrast, lower levels of IL-12 should reduce susceptibility because IL-12 antagonists can protect NOD mice from diabetes (Trembleau et al., 1997).

[0149] Materials and Methods

[0150] Genotyping

[0151] We tested a total of 249 affected sibpairs, including families that were previously described (Morahan et al., 1996) and an additional 120 families obtained from the British Diabetes Association. An additional independent cohort of 235 predominantly simplex families was also recruited into the Australian IDDM DNA Repository. DNA from individuals from multiplex families were typed using either anonymous microsatellite markers (Weissenbach et al., 1992) or the highly polymorphic repeat within GABRA1 (Johnson et al., 1992). We tested polymorphisms in and around IL12B as described (Huang et al., in press). The D5S2937 marker is a simple sequence repeat which was generated from inspection of the draft sequence of the BAC 9p16 from 5q33-34 obtained from the DOE's Joint Genome Institute (ftp://ft]2.1gi-psf.orgipub/JGI-data/Human/Ch5/Draft/). primers to amplify this TAA repeat were 5′-GGGTAAGCGATTCAAA-CATT-3′ (<400>137) (forward) and 5′GGTATTGCATTGTAGGCACAT-3′ (<400>138) (reverse). D5S2940 is a C(T)n repeat located 12 kb centromeric of the 3′ UTR and was amplified with primers 5′GGGCAACAAGAGTGAAACT-3′ (<400>139) and 5′-TCAAAAGAGGTCCGTCTAAA-3′ (<400>140).

[0152] Genetic Analyses

[0153] We carried out multipoint linkage analysis using the MAPMAKER/Sibs software program (Kruglyak et al., 1995), and TDT analyses (Spielman et al., 1993) using both the GAS software package (Young, A., 1994) and Tsp program (Martin et al., 1998).

[0154] Gene Expression

[0155] We typed EBV-transformed cell lines from the 4th Asia-Oceania Histocompatibility Workshop cell line panel Degli-Esposti et al., 1993) for the IL12B 3′ UTR allele, and cell lines representing the 1/1 and 2/2 genotypes were selected. We isolated total RNA from these cell lines using guanadinium thiocyanate and purified it by CsCl-density gradient centrifugation. Northern-blot analysis was performed by standard methods (Sambrook et al., 1989) with human IL12B and GAPDH cDNA probes. The levels of IL12B MRNA in each cell line relative to GAPDH was determined by densitometry in three separate experiments. Similar results were obtained by RT-PCR (data not shown).

EXAMPLE 8 Polymorphisms Haplotypes as a Marker of Disease Susceptibility or Resistance

[0156] The combination of particular polymorphisms is used to define IL12B haplotypes. These haplotypes are used to test for susceptibility or resistance to immune related diseases in which IL12 production and/or Th1-Th2 regulation may be relevant.

[0157] An example of the use of such haplotypes is demonstrated in the table below. Combining promoter and 3′ UTR alleles generates 4 haplotypes. The appearance of these haplotypes may be compared between different groups which differ in a relevant phenotype. To illustrate this point, consider subjects with diabetes and first degree relatives who do not have diabetes but who have autoantibodies (i.e. “preclinical”). The table shows that there is a difference in the proportion of haplotype C homozygous individuals in these groups. Thus haplotypes may be used to predict likelihood to proceed from early autoimmunity to diabetes. Haplotypes may be used in this way to test for susceptibility or resistance to other disease conditions or predisposition to mounting Th1 or Th2 type immune responses.

[0158] Haplotype analysis of IDDM and preclinical subjects. Subjects Haplotype C/C Other haplotypes P IDDM 122 124 0.005 Preclinical 9 32

[0159] Those skilled in the art will appreciate that the invention described herein is susceptible to variations and modifications other than those specifically described. It is to be understood that the invention includes all such variations and modifications. The invention also includes all of the steps, features, compositions and compounds referred to or indicated in this specification, individually or collectively, and any and all combinations of any two or more of said steps or features. TABLE 7 Sequences of Exon-Intron boundaries. Intron Sequence 1 <400>116 GCCCAGAGCAAGGTAAGCACTTCC . . . CCCTTCTTATAGATG TGTCACCAG <400>117 2 <400>118 TGAAGAAAGATGGTAACCAGCCTC . . . TGTGCATTCCAGTTTATGTCGTAG <400>119 3 <400>120 AGGACCAGAAAGGTAATTCTATAC . . . TTTCAAATCCAGAACCCAAAAATA <400>121 4 <400>122 AAGCAGCAGAGGGTGAGTGAAACT . . . CTTTGACTTCAGCTCTTCTGACCC <400>123 5 <400>124 TCAGGGACATCAGTGAGTTTTGGA . . . CCTCTTCCACAGTCAAACCTGACC <400>125 6 <400>126 AAGAGAGAAAAGGTAAGAAGTGAT . . . TCTCTTTTGCAGAAAGATAGAGTC <400>127 7 <400>128 CCCTGCAGT TAGGTGAGCAGGCCC . . . ATTCTCTTCCAGGTTCTGATCCAG <400>129

[0160] Sequences of Exon-Intron boundaries. The complete IL12p40 genomic sequence was determined using PAC 93.1 as a template. The sequence has been deposited in Genbank. Exon-intron boundaries were determined by comparison with published CDNA sequences (Gubler et al., 1991; Wolf et al., 1991). Exon sequences are shown in bold; splice donor and acceptor sites are single underlined. The start and stop codons (double underlined) are the first and last codons in exons 2 and 7 respectively. Sizes of introns are indicated in FIG. 1C. TABLE 8 Comparison of genomic and published IL12p40 sequences Region DNA source Position Sequence Comment Promoter PAC 93-1 544 <400>3 AGTTTTTTTTTTTTAATTTTCAAGGTGCTT ----------------*------------- No RE difference HSU89323 <400>4 AGTTTTTTTTTTTTAAATTTCAAGGTGCTT Could not confirm Promoter PAC 93-1 885 <400>5 AACATACCTGCAATCTGCTTTGTCCACTTA -----------------*------------ No RE difference HSU89323 <400>6 AACATACCTGCAATCTGATTTGTCCACTTA Could not confirm Promoter PAC 93-1 1973 <400>7 CTAAACCCTTTGCCCTTCATCTCATCCTC --------------*-------------- No RE difference HSU89323 <400>8 CTAAACCCTTTGCC-TTCATCTCATCCTC Could not confirm Exon 6 PAC 93-1 14041 <400>9 TCAAACCTGACCCACCCAAGAACTTGCAGC HUMCLMF40 = PAC -------------------*---------- Gives K -> N change HUMNKSFP40 <400>10 TCAAACCTGACCCACCCAACAACTTGCAGC Could not confirm Exon 7 PAC 93-1 16117 <400>11 AGATAGAGTCTTCACGGACAAGACCTCAGC HUMCLMF40 = PAC ---------------*-------------- Silent change HUMNKSFP40 <400>12 AGATAGAGTCTTCACCGACAAGACCTCAGC Could not confirm 3′ UTR PAC 93-1 16974 <400>13 TTGTATAGTTAGATGCTAAATGCT L3 same; TaqI− (exon 8) ----------*------------- Creates a TaqI site HUMNKSFP40 <400>14 TTGTATAGTTCGATGCTAAATGCT L26 same; TaqI+

[0161] TABLE 9 Detection and Confirmation of IL12p40 polymorphisms Product Reaction Polymorphism Primers (5′->3′) size conditions* Intron 1 3696 GGCTTAAAGGGGCCAAGT <400>15 401 Standard AGGGAGCACTATCCCTCAGC <400>16 Intron 1 3757 GGCTAAAGGGGCCAAGT <400>17 401 Standard AGGGAGCACTATCCCTCAGC <400>18 Intron 1 4572 ATGTTATCTCATTGCCTTC <400>19 511-513 Standard AAGTGGTTCTGAAACCACTG <400>20 Intron 1 4793 ATGTTATCTCATTGCCTTTC <400>21 511-513 Standard AAGTGGTTCTGAAACCACTG <400>22 Intron 2 8798 GGGAAGACTAAGCTCTACTG <400>23 128-131 Standard GGATTTCGTTCCCTCTGTTT <400>24 Intron 2 8930 GGGAAGACTAAGCTCTACTG <400>25 413 Standard CAACGAACCAAGACTGTCAT <400>26 Intron 2 8944 GGGAAGACTAAGCTCTACTG <400>27 413 Standard CAACGAACCAAGACTGTCAT <400>28 Intron 3 9910 TTCTAAGCCATTCGCTCCTG <400>29 188 Standard GTTAATTCATTACACTCACC <400>30 Intron 4 11244 TACTTCTGCTGACACCACTA <400>31 436 Standard GAACTAGGATCAAATTGTATAC <400>32 Intron 4 11563 GGTTACATAATCATATGTA <400>33 254-258 Standard GTTAGGATTTCAGGTGTGAG <400>34 Intron 7 16521 TAGCTCATCTTGGAGCGAAT <400>35 982 70 s at 72° C. AACATTCCATACATCCTGGC <400>36 Exon 7 16117 GAAAGGCCATGCACCTAAC <400>37 1,285 90 s at 72° C. TCCAGGTGCACTGAGAGT <400>38 Exon 8 16974 TTTGGAGGAAAAGTGGAAGA <400>39 300 2′ final at 72° C. AACATTCCATACATCCTGGC <400>40 TaqI digestion Detection Number Number Number homozygous for Number Method screened sequenced PAC allele non-PAC allele Heterozygous SSCP 23 16 1 11 4 SSCP 23 16 3 10 3 SSCP 27 15 1 12 2 SSCP 27 13 2 10 1 SSCP 27 6 4 2 0 SSCP 27 9 1 7 1 SSCP 27 8 2 5 1 SSCP 27 9 3 5 1 SSCP 24 14 2 12 0 SSCP see Table 5 EcoRV, HindIII 15 1 14 0 digest, SSCP direct sequence 9 9 0 0 see Table 5

[0162] TABLE 10 Allelic differences in IL12p40 sequences. Intron DNA Position Sequence No. Alleles 1 L26 TCTTTAATAATAACTCCCTTTT <400>41 ---------*------------ PAC 3696 TCTTTAATAGTAACTCCCTTTT <400>42 L26 GCCCACCCAAGTGTCATTGG <400>43 -----------*-------- PAC 3757 GCCCACCCAAGCGTCATTGG <400>44 L26 TCAAGCCTG-TCTGTTTAA <400>45 ---------**--------- PAC 4572-3 TCAAGCCTGTGTCTGTTTAA <400>46 L26 CCGCCTAGACTTAGTAG <400>47 ---------*------- PAC 4793 CCGCCTAGAGTTAGTAG <400>48 2 L26 TAAAAATAATAATAATAATAATAATAATAATG <400>49 2 ------***----------------------- 2 PAC 8798-8800 TAAAAA---TAATAATAATAATAATAATAATG <400>50 L26 CTCCTCAGTCTATAAGTAACAATAACTA <400>51 ------*-------------*------- PAC 8930; 8944 CTCCTCGGTCTATAAGTAACGATAACTA <400>52 3 L26 CGCTCATAAGGGTTAAAAACAACAACAAC <400>53 ----------*------------------ PAC 9910 CGCTCATAAGAGTTAAAAACAACAACAAC <400>54 4 L26 TCTCCAAGTGCAAAAAGACATAATCAGCAG <400>55 ------------*----------------- PAC 11244 TCTCCAAGTGCATAAAGACATAATCAGCAG <400>56 L26 TATATATATAT----AAAATGTGTATACA <400>57 3 -----------****-------------- PAC 11563-6 TATATATATATATATAAAATGTGTATACA <400>58 7 L26 AGAGCATGGAGGACTTGCA <400>59 ---------*--------- PAC 16521 AGAGCATGGCGGACTTGCA <400>60

[0163] TABLE 11 Allele Frequencies of IL12p40 variants. Hardy- Frequency Weinberg Polymorphism No. tested Allele 1 Allele 2 Allele 3 equilibrium Intron 4 11563 336 0.79 0.2 0.01 Yes Exon 8 16974 382 0.82 0.18 Yes

[0164] Allele frequencies were determined by genotyping unrelated subjects of diverse European descent. The intron 4 TA repeat polymorphism was detected on denaturing bis-acrylamide gels. The exon 8 TaqI allele was detected as follows: 2 ul of products digested with 1 unit of TaqI in a 1o ul reaction volume and incubate at 65° C. for 2 hours. The number of individuals with each genotype did not differ from that expected if the alleles were in Hardy-Weinberg equilibrium. TABLE 12 Primers used for sequencing PAC93-1 Forward primers: Reverse primers: <400>61 PF GGAAGGCGCCCCAGATGTA P9R GAATTGCATGCTGGGTTCTG <400>86 <400>62 P3F TCAGACACATTAACCTTGCA P8R CTGTGGCTTCCAGAGGTTAC <400>87 <400>63 P4F CAATAGACAAGTGATTTCACTG P7R TAATGTGGTCATTGGCAGGT <400>88 <400>64 P6F ATGCTTAATTATAACTATATTC P5R CAGATGAGTCCTTGTGCCCC <400>89 <400>65 P7F CCATAATAGGTTCATTGCCC P4R ACCCGGGCCAGAGCAGCG <400>90 <400>66 Int1-3F GGCTTAAAGGGGCCAAGT P3R GCGGAATAAAGATATCTCTC <400>91 <400>67 Int1-6F CCCACCACCATCACCTCT P2R GATGAGATGAAGGCAAAGG <400>92 <400>68 Int1-5F ATGTTATCTCATTGCCTTTC PR TCACCAGGGATGCTTCCAGG <400>93 <400>69 Int1 (F) GAAGAAAGGGGAGAATCAAG Int1-5R GGTTACCCACATTCCATC <400>94 <400>70 Int2F GGAAAATGCAATGCCATATC Int1-2Fr CTTATGCCATGGATCATGTC <400>95 <400>71 Int2-1F ATCCTGAATTTCCTCAACTG Int1-7R AAGTGGTTCTGAAACCACTG <400>96 <400>72 Int2-2F AGAGACTGTCTGTATCCCAT Int1-4R CCAGAGTGTCTGATTCAGC <400>97 <400>73 Int2-4F AGGCCTGAGCCAGGGGTAT Int1-3R AAGGCAAGCCATCTGATACA <400>98 <400>74 Ex3F TTCTAAGCCATTCGCTCCTG Int2R AGGCCAACGATCTAAGCATG <400>99 <400>75 Int4F ATTCTGGACGTTTCACCTGC Int2-1R GGAGTGGCAGAGGCCTGG <400>100 <400>76 Int4F-4 TACTTCTGCTGACACCACTA Ex3-R CACCATTTCTCCAGGGGCA <400>101 <400>77 F-Int4.3 GGATGAAGGAGACATACACT Ex3-1R CAACGAACCAAGACTGTCAT <400>102 <400>78 IL-12A GCCGTTCACAAGCTCAAGTA Int3-1R GTTAATTCATTACACTCACC <400>103 <400>79 Int5F GGACTTCTTTCTTAGAATAT Int4-8R ATAGGTCACTGAGAGGTTGC <400>104 <400>80 IL-12E ATCAAACCTGACCCACCCAA Int4-3R AGCTTGTTGTATCCTTCCAG <400>105 <400>81 Int6F ATGTGATCCTTCTTTGACTG Int4R TCATACTCCTTGTTGTCCCC <400>106 <400>82 Int6-1F GAAAGGCCATGCACCTAAC 5-1R CGGCTAGCTGTAAGATCTGA <400>107 <400>83 IL-12TAQF TAGCTCATCTTGGAGCGAAT Int5R CATGGAACTAAGCTGAGCCC <400>108 <400>84 #6 TTTGGAGGAAAAGTGGAAGA IL-12 * R CGCAGAATGTCAGGGAGAAG <400>109 <400>85 T7 AATACGACTCACTATAG Int6R TCCAGGTGCACTGAGAGT <400>110 Int6-1R TTCTAGCACAATTGCCTTGCCT <400>111 IL-12B AACATTCCATACATCCTGGC <400>112 Ex8-1R GCAGGAAGACACTGACTTTG <400>113 Ex8-2R GCCTTCCAGACACTTACGGT <400>114 T3 ATTAACCCTCACTAAAG <400>115

[0165] TABLE 13 Analyses of allelic transmission to affected offspring TDT of polymorphisms in IL12B Polymorphism Allele Freq. Trans Not P 3′ UTR 1 0.79 171 122 0.0025 2 0.21 122 171 — intron 4 1 0.79 137  85 0.00029 2 0.20  85 131 — 3 0.01  0  6 — promoter 1 0.56 176 191 0.77 2 0.44 191 176 — TDT at a centromeric locus, D5S2937 Allele Freq Trans. Not P 1 0.02  4  6 — 2 0.07 30 14 0.011 3 0.10 30 50 — 4 0.23 67 76 — 5 0.07 19 14 — 6 0.17 63 61 — 7 0.04 17 10 — 8 0.21 74 66 — 9 0.09 24 31 — TDT allowing for multiple affected family members (T_(sp)) Marker DF χ² P D5S2937 8 18.292 0.0191 3′ UTR 1 12.694 0.0004 Intron 4 2 10.549 0.0051 promoter 1 0.305 0.5809

[0166] TDT analyses (Spielman et al., 1993) of polymorphisms in and around IL12B were carried out on the data from the linkage study (FIG. 3). Markers are shown in order from centromere to telomere (Huang et al., in press). The D5S2937 marker is a simple sequence repeat which was generated from inspection of the draft sequence of a cosmid from 5q33-34. This marker was placed on the physical map in relation to IL12B. Note that no correction was made for testing multiple alleles at this locus. For clarity , only P<0.1 is shown. The data were used to calculate the T_(sp) statistics shown, which corrects for multiple affected individuals per family (Martin et al., 1998). DF, degrees of freedom. No correction was made for testing multiple alleles at the D5S2937 locus. TABLE 14 TDT of an independent cohort of simplex families Polymorphism Allele Freq Trans Not Trans. P IL12B promoter 1 0.5 101 96 — 2 0.5 96 101 — IL12B 3′ UTR 1 0.78 101 55 0.00014 2 0.22 55 101 — D5S2940 1 0.04 7 12 — 2 0.5 93 97 — 3 0.45 98 89 — 4 0.01 5 5 —

[0167] 235 simplex families with one affected child were genotyped for the IL12B promoter or 3′ UTR alleles, as well as for D5S2940. Note that although 235 families were tested, the high homozygosity rate for the 3′ UTR polymorphism meant that most parents were not informative for this marker. Allele frequencies were calculated based on parental genotypes. For clarity, only P<0.1 is shown.

BIBLIOGRAPHY

[0168] Bennett S, Todd J. Ann Rev Genet 30: 343-70 (1996)

[0169] Boehnke M. et al., Am J Hum Genet 49: 1174-1188 (1991)

[0170] Degli-Esposti, M., et al., Hum. Immunol., 38:3-16 (1993)

[0171] Fu, J., et al., Diabetologia 41:228-232 (1998)

[0172] Gubler U. et al., Proc. Natl. Acad. Sci. U.S.A. 88: 4143-4147 (1991)

[0173] Hicks A. A. et al., Genomics 20: 285-288 (1994)

[0174] Huang, D., et al., Genes Immunity (in press)

[0175] Ioannou P. A., et al., Nat Genet 6: 84-89 (1994)

[0176] Johnson K. J., et al., Genomics., 14: 745-748 (1992)

[0177] Katz, J., et al., Science., 268:1185-1188 (1995)

[0178] Kruglyak, L. & Lander, E., Am. J Hum. Genet., 57:439-454 (1995)

[0179] Larsen, Z., et al., Autoimmunity 31:35-42 (1999)

[0180] LeCam, A & Legraverend, C., Eur. J. Biochem., 231:620-627 (1995)

[0181] Ma X, et al., Journal of Experimental Medicine 183: 147-157 (1996)

[0182] Martin, E., et al., Am. J. Hum. Genet 61:439-448 (1998)

[0183] Morahan, G., et al., Science 272:1811-1813 (1996)

[0184] Osoegawa K. et al., Genomics 52: 1-8 (1998)

[0185] Ramarao C S, Kincade-Denker J M, Perez D M, Gaivin R J, Riek R P, Graham R M. Journal of Biological Chemistry 1992; 267

[0186] Risch N Am J Hum Genet 40: 1-14 (1987)

[0187] Robinson, W., et al., Genetic Epidemiol 10:273-288 (1993)

[0188] Sambrook J, Fritsch, E F & Maniatis T 2nd ed. Molecular Cloning. (Cold Spring Harbour Laboratory Press: New York, ed. 2, 1989), pp. Pages.

[0189] Spielman R., et al., Am. J. Hum. Genet. 52:506-516 (1993)

[0190] Szelachowska, M., et al., Horm. Metab. Res., 29:168-171 (1997)

[0191] Tone Y., et al., Eur. J. Immunol. 26:1222-27 (1996)

[0192] Trembleau, S., et al., J. Exp. Med., 181:817-821 (1995)

[0193] Trembleau, S., et al., Eur. J. Immunol., 27:2330-2339 (1997)

[0194] Trinchieri G. Ann Rev Immunol 13:251-276 (1995)

[0195] Warrington J. A. & Bengtsson U., Genomics 24: 395-398 (1994)

1 140 1 419 DNA mammalian 1 cagcattagc gtgcgggccc aggaccgcta ctatagctca tcttggagcg aatgggcatc 60 tgtgccctgc agttaggttc tgatccagga tgaaaatttg gaggaaaagt ggaagatatt 120 aagcaaaatg tttaaagaca caacggaata gacccaaaaa gataatttct atctgatttg 180 ctttaaaacg tttttttagg atcacaatga tatctttgct gtatttgtat agttcgatgc 240 taaatgctca ttgaaacaat cagctaattt atgtatagat tttccagctc tcaagttgcc 300 atgggccttc atgctattta aatatttaag taatttatgt atttattagt atattactgt 360 tatttaacgt ttgtctgcca ggatgtatgg aatgtttcat actcttatga cctgatcca 419 2 419 DNA mammalian 2 cagcattagc gtgcgggccc aggaccgcta ctatagctca tcttggagcg aatgggcatc 60 tgtgccctgc agttaggttc tgatccagga tgaaaatttg gaggaaaagt ggaagatatt 120 aagcaaaatg tttaaagaca caacggaata gacccaaaaa gataatttct atctgatttg 180 ctttaaaacg tttttttagg atcacaatga tatctttgct gtatttgtat agttagatgc 240 taaatgctca ttgaaacaat cagctaattt atgtatagat tttccagctc tcaagttgcc 300 atgggccttc atgctattta aatatttaag taatttatgt atttattagt atattactgt 360 tatttaacgt ttgtctgcca ggatgtatgg aatgtttcat actcttatga cctgatcca 419 3 30 DNA mammalian 3 agtttttttt ttttaatttt caaggtgctt 30 4 30 DNA mammalian 4 agtttttttt ttttaaattt caaggtgctt 30 5 30 DNA mammalian 5 aacatacctg caatctgctt tgtccactta 30 6 30 DNA mammalian 6 aacatacctg caatctgatt tgtccactta 30 7 29 DNA mammalian 7 ctaaaccctt tgcccttcat ctcatcctc 29 8 28 DNA mammalian 8 ctaaaccctt tgccttcatc tcatcctc 28 9 30 DNA mammalian 9 tcaaacctga cccacccaag aacttgcagc 30 10 30 DNA mammalian 10 tcaaacctga cccacccaac aacttgcagc 30 11 30 DNA mammalian 11 agatagagtc ttcacggaca agacctcagc 30 12 30 DNA mammalian 12 agatagagtc ttcaccgaca agacctcagc 30 13 24 DNA mammalian 13 ttgtatagtt agatgctaaa tgct 24 14 24 DNA mammalian 14 ttgtatagtt cgatgctaaa tgct 24 15 18 DNA mammalian 15 ggcttaaagg ggccaagt 18 16 20 DNA mammalian 16 agggagcact atccctcagc 20 17 18 DNA mammalian 17 ggcttaaagg ggccaagt 18 18 20 DNA mammalian 18 agggagcact atccctcagc 20 19 20 DNA mammalian 19 atgttatctc attgcctttc 20 20 20 DNA mammalian 20 aagtggttct gaaaccactg 20 21 20 DNA mammalian 21 atgttatctc attgcctttc 20 22 20 DNA mammalian 22 aagtggttct gaaaccactg 20 23 20 DNA mammalian 23 gggaagacta agctctactg 20 24 20 DNA mammalian 24 ggatttcgtt ccctctgttt 20 25 20 DNA mammalian 25 gggaagacta agctctactg 20 26 20 DNA mammalian 26 caacgaacca agactgtcat 20 27 20 DNA mammalian 27 gggaagacta agctctactg 20 28 20 DNA mammalian 28 caacgaacca agactgtcat 20 29 20 DNA mammalian 29 ttctaagcca ttcgctcctg 20 30 20 DNA mammalian 30 gttaattcat tacactcacc 20 31 20 DNA mammalian 31 tacttctgct gacaccacta 20 32 22 DNA mammalian 32 gaactaggat caaattgtat ac 22 33 19 DNA mammalian 33 ggttacataa tcatatgta 19 34 20 DNA mammalian 34 gttaggattt caggtgtgag 20 35 20 DNA mammalian 35 tagctcatct tggagcgaat 20 36 20 DNA mammalian 36 aacattccat acatcctggc 20 37 19 DNA mammalian 37 gaaaggccat gcacctaac 19 38 18 DNA mammalian 38 tccaggtgca ctgagagt 18 39 20 DNA mammalian 39 tttggaggaa aagtggaaga 20 40 20 DNA mammalian 40 aacattccat acatcctggc 20 41 22 DNA mammalian 41 tctttaataa taactccctt tt 22 42 22 DNA mammalian 42 tctttaatag taactccctt tt 22 43 20 DNA mammalian 43 gcccacccaa gtgtcattgg 20 44 20 DNA mammalian 44 gcccacccaa gcgtcattgg 20 45 18 DNA mammalian 45 tcaagcctgt ctgtttaa 18 46 20 DNA mammalian 46 tcaagcctgt gtctgtttaa 20 47 17 DNA mammalian 47 ccgcctagac ttagtag 17 48 17 DNA mammalian 48 ccgcctagag ttagtag 17 49 32 DNA mammalian 49 taaaaataat aataataata ataataataa tg 32 50 29 DNA mammalian 50 taaaaataat aataataata ataataatg 29 51 28 DNA mammalian 51 ctcctcagtc tataagtaac aataacta 28 52 28 DNA mammalian 52 ctcctcggtc tataagtaac gataacta 28 53 29 DNA mammalian 53 cgctcataag ggttaaaaac aacaacaac 29 54 29 DNA mammalian 54 cgctcataag agttaaaaac aacaacaac 29 55 30 DNA mammalian 55 tctccaagtg caaaaagaca taatcagcag 30 56 30 DNA mammalian 56 tctccaagtg cataaagaca taatcagcag 30 57 25 DNA mammalian 57 tatatatata taaaatgtgt ataca 25 58 29 DNA mammalian 58 tatatatata tatataaaat gtgtataca 29 59 19 DNA mammalian 59 agagcatgga ggacttgca 19 60 19 DNA mammalian 60 agagcatggc ggacttgca 19 61 19 DNA mammalian 61 ggaaggcgcc ccagatgta 19 62 20 DNA mammalian 62 tcagacacat taaccttgca 20 63 22 DNA mammalian 63 caatagacaa gtgatttcac tg 22 64 22 DNA mammalian 64 atgcttaatt ataactatat tc 22 65 20 DNA mammalian 65 ccataatagg ttcattgccc 20 66 18 DNA mammalian 66 ggcttaaagg ggccaagt 18 67 18 DNA mammalian 67 cccaccacca tcacctct 18 68 20 DNA mammalian 68 atgttatctc attgcctttc 20 69 20 DNA mammalian 69 gaagaaaggg gagaatcaag 20 70 20 DNA mammalian 70 ggaaaatgca atgccatatc 20 71 20 DNA mammalian 71 atcctgaatt tcctcaactg 20 72 20 DNA mammalian 72 agagactgtc tgtatcccat 20 73 19 DNA mammalian 73 aggcctgagc caggggtat 19 74 20 DNA mammalian 74 ttctaagcca ttcgctcctg 20 75 20 DNA mammalian 75 attctggacg tttcacctgc 20 76 20 DNA mammalian 76 tacttctgct gacaccacta 20 77 20 DNA mammalian 77 ggatgaagga gacatacact 20 78 20 DNA mammalian 78 gccgttcaca agctcaagta 20 79 20 DNA mammalian 79 ggacttcttt cttagaatat 20 80 20 DNA mammalian 80 atcaaacctg acccacccaa 20 81 20 DNA mammalian 81 atgtgatcct tctttgactg 20 82 19 DNA mammalian 82 gaaaggccat gcacctaac 19 83 20 DNA mammalian 83 tagctcatct tggagcgaat 20 84 20 DNA mammalian 84 tttggaggaa aagtggaaga 20 85 17 DNA mammalian 85 aatacgactc actatag 17 86 20 DNA mammalian 86 gaattgcatg ctgggttctg 20 87 20 DNA mammalian 87 ctgtggcttc cagaggttac 20 88 20 DNA mammalian 88 taatgtggtc attggcaggt 20 89 20 DNA mammalian 89 cagatgagtc cttgtgcccc 20 90 18 DNA mammalian 90 acccgggcca gagcagcg 18 91 20 DNA mammalian 91 gcggaataaa gatatctctc 20 92 19 DNA mammalian 92 gatgagatga aggcaaagg 19 93 20 DNA mammalian 93 tcaccaggga tgcttccagg 20 94 18 DNA mammalian 94 ggttacccac attccatc 18 95 20 DNA mammalian 95 cttatgccat ggatcatgtc 20 96 20 DNA mammalian 96 aagtggttct gaaaccactg 20 97 19 DNA mammalian 97 ccagagtgtc tgattcagc 19 98 20 DNA mammalian 98 aaggcaagcc atctgataca 20 99 20 DNA mammalian 99 aggccaacga tctaagcatg 20 100 18 DNA mammalian 100 ggagtggcag aggcctgg 18 101 19 DNA mammalian 101 caccatttct ccaggggca 19 102 20 DNA mammalian 102 caacgaacca agactgtcat 20 103 20 DNA mammalian 103 gttaattcat tacactcacc 20 104 20 DNA mammalian 104 ataggtcact gagaggttgc 20 105 20 DNA mammalian 105 agcttgttgt atccttccag 20 106 20 DNA mammalian 106 tcatactcct tgttgtcccc 20 107 20 DNA mammalian 107 cggctagctg taagatctga 20 108 19 DNA mammalian 108 catggaacta agctgagcc 19 109 20 DNA mammalian 109 cgcagaatgt cagggagaag 20 110 18 DNA mammalian 110 tccaggtgca ctgagagt 18 111 22 DNA mammalian 111 ttctagcaca attgccttgc ct 22 112 20 DNA mammalian 112 aacattccat acatcctggc 20 113 20 DNA mammalian 113 gcaggaagac actgactttg 20 114 20 DNA mammalian 114 gccttccaga cacttacggt 20 115 17 DNA mammalian 115 attaaccctc actaaag 17 116 24 DNA mammalian 116 gcccagagca aggtaagcac ttcc 24 117 24 DNA mammalian 117 cccttcttat agatgtgtca ccag 24 118 24 DNA mammalian 118 tgaagaaaga tggtaaccag cctc 24 119 24 DNA mammalian 119 tgtgcattcc agtttatgtc gtag 24 120 24 DNA mammalian 120 aggaccagaa aggtaattct atac 24 121 24 DNA mammalian 121 tttcaaatcc agaacccaaa aata 24 122 24 DNA mammalian 122 aagcagcaga gggtgagtga aact 24 123 24 DNA mammalian 123 ctttgacttc agctcttctg accc 24 124 24 DNA mammalian 124 tcagggacat cagtgagttt tgga 24 125 24 DNA mammalian 125 cctcttccac agtcaaacct gacc 24 126 24 DNA mammalian 126 aagagagaaa aggtaagaag tgat 24 127 24 DNA mammalian 127 tctcttttgc agaaagatag agtc 24 128 24 DNA mammalian 128 ccctgcagtt aggtgagcag gccc 24 129 24 DNA mammalian 129 attctcttcc aggttctgat ccag 24 130 18340 DNA mammalian 130 caatagacaa gtgatttcac tgcgggaaga caattcagag ccctgttcca ggctcctcac 60 attgattctc tctgtcttct tccactcctc tttgtcatct ttgatgtccc cttgtgagct 120 acgaaaagac tttctgggac acgacaggat aaaaaaataa ataagtgcaa gcagccattc 180 attaaacgtt tagccaggat gctgctttaa ctgcatccca tcatatctca ttaatcttca 240 caccagtcct gagatcaggt actattatta acccgatttt acagatgtga ggaactgagg 300 cttaacgaag gtaagtaact tgcaggtgcg ggtatccagc tctctaactc cagagcccat 360 gctcttaaaa ccctattact tgtccctggt ggaggtgaac actgggggcc ctttcatata 420 ggactagccc tcgggctgca atctgagcgg aaaagggagg atgagggcat acttcgaagc 480 ttcttttgca taactggcgc tggattttta ctgagacttt acgttacagt tttttttttt 540 taattttcaa ggtgctttta cgaacacatg aataaaatat ttgtgtcatt ttgaacctta 600 cttgtcttat tttatgcatg tatttattta tgggggggca caaggactca tctgtggtgg 660 tgcagccact gtaaataaat tagtgaaact acttcacgtc aatttctgtt cagtacactt 720 tagtgatgga tcggaggaaa ttaatacatg tttacaaaaa gcccctcccc cagttgttac 780 atatgcctca gagataccag ttgtgaaaag tgcaggtgca cttacacaca tacgcacaca 840 caccccacaa atggtatcat acgaaaaaac atacctgcaa tctgctttgt ccacttaatt 900 gtatatcttg gatacagaac ttgtttcact ggaaggctaa aaggcaaagt ctggggaggc 960 ctagaggaca caggggatgg gaggaggcgc tctgagctgg atgtaaggtc tccacccacg 1020 gccagagcac aaggtcggat aaccagtggg cctgccggct tggctgcctg ggccctcccc 1080 tgccgagaca aacggctgga gggaggaagt gtgcggctgg gaagctccgc tgctctggcc 1140 cgggtttccc atttccccct tcccgcgctg agacggcgag gaaagttagc ccggaaatct 1200 gcgcccgcct aaaacccggc ctggtcccag ccaccgcccc aggaacttcc cccaccgcag 1260 gggcggaggt cgagagcagg gatggagaag tggacctgcg cgggtggact ccggggcgcg 1320 ggtggactcc ggggcgcggg gggactccga ggagcgggtg gactgtgggg cgcgggtacc 1380 gtctcgcagc gacctctgtc ggcggctctg gggatggccc gcatctgtct gcgtgtacct 1440 ggtatacgtg caggtacatg ttcctgttca cgtgcagact gggcggggga tgggggggtc 1500 cacaccggtg tacacctttg catacctctt agcaacttga aattccacca cgagagatat 1560 ctttattccg ctattcctgt gcatctgcac ggagccccta gggccataga tttgtgtgca 1620 aatgaaatga ggatgtagtc tgggtgccca agggggggtg ccttgagtgt ggttgtctgt 1680 atgcctccct gagggtattt cactttctgc tcccatccgc ccctatgagc gagtacctat 1740 gagcacagga tgtgcacata tttgagtctt attagtggta cacgcagttt tatcatctcc 1800 ccaggtctgt gtctgtatga aatgtgcatg ggtgtgtgtg tgcacgcgtg tgttcccact 1860 cggggaatgt ggggagaggt gcatggagcc aagatgggtg gtaaatagta tgtttctgaa 1920 attaaaggac taatgtggag gaaggcgccc cagatgtact aaaccctttg cccttcatct 1980 catcctctct gacttgggaa gaaccaggat tttgttttta agcccttggg catacagttg 2040 ttccatcccg acatgaactc agcctcccgt ctgaccgccc cttggccttc cttcttcctc 2100 gatctgtgga acccagggaa tctgcctagt gctgtctcca agcaccttgg ccatgatgta 2160 aacccagaga aattagcatc tccatctcct tccttattcc ccacccaaaa gtcatttcct 2220 cttagttcat tacctgggat tttgatgtct atgttccctc ctcgttattg atacacacac 2280 agagagagac aaacaaaaaa ggaacttctt gaaattcccc cagaaggttt tgagagttgt 2340 tttcaatgtt gcaacaagtc agtttctagt ttaagtttcc atcagaaagg agtagagtat 2400 ataagttcca gtaccagcaa cagcagcaga agaaacaaca tctgtttcag ggccattgga 2460 ctctccgtcc tgcccagagc aaggtaagca cttcccaagc ccctacctcc ctcccctccc 2520 tgtgggcctg cagctgtcca ggtgtagaaa ccgttagtgt gctaccccag cagctggcag 2580 gagggagttg gtggattcct ggaagcatcc ctggtgagtc atctgctgga acattagtga 2640 aaacttagta ctctagggac cgatgtacag tgtccatttt aaaagccacc taataataac 2700 tgtatagcaa gatctgtgtg tatgcatagt ttgtggaaat gtttgtttta tcttattttg 2760 aagtggtgtg tattgatgta taaaagtata ttcctaaatg ttaatgccca tcagttaaag 2820 gattgtatag agctaaagtg agtggtgcct gccttactat tgaaattttt aaaaagcctt 2880 tcgtgcattc cttaaagtaa ttggattcat aattataata atgttacaaa tcagacttgc 2940 tcccatattt gtgatggtct tggtcgtcag ttgtgatatc aaccaaaatg acagctggga 3000 tccccattct tgtggattaa ctaactttgg ccccagttaa aaaatgaaaa gctattattg 3060 cttcctaaag agtttttaaa tctgtgagaa gggggaaaaa aaggtttttt tacttgccca 3120 ggtaaaattg tgtgcaacaa caatgtcatt ttaacaaagg gattactaaa ccccaggtga 3180 tgacccactt tttcaaacaa ggaattgcaa gatactagat ggaatgtggg taacctctta 3240 gagtttagtt tactggaatc tgaaattgta tgatttccgt acattccttc atgctactaa 3300 taagtcatgg aatccctctg tgctggactc tgggggtaaa gtgcaaaaca agatagacat 3360 gatccatggc ataagagagt tcactcagtg tggcagagaa gacaaacagt aaagaagaga 3420 ctgtattgtt gccattgtag taaatgctgt ggaaggaggg gagcaaatag tgggtcctga 3480 cttcatctag gcaccatgac acttcacgtg aattatgtca ctaactcctt accacagtag 3540 catgcccatt ttatagatca ggagtgtggg gcttaaaggg gccaagtgac tcacccagag 3600 tcacacagtt ctagaagtct gcctggccct caaactaggg atctttgcat gtgccaccca 3660 tgccatctgt gactatatct ttttattctt taatagtaac tcccttttct aattaaaggt 3720 aacaaacaaa acttaaaaaa gagatgccca cccaagcgtc attggcatgc tgatgttggc 3780 accagtgttg ggaagccctt agcatactcc aggaagtagg agtgtgtaac gtggggtccc 3840 tttgtccttc atgcaagggt ttcaagagtt tagaaaacct atgaaattgc acacacaaaa 3900 atgtgtttta atcatcaaga ctctcagact taccatgctg agaaatgtgg gctgagggat 3960 agtgctccct agtatcagct gatgggccag agagccaaag gaggagaccc accaccatca 4020 cctctcctgg acagtgctct gtggtttcaa atgtaggtga tactaaaatg ggagttgttt 4080 cttagaacca tggccggggt tcccttgacc ctgaagtgca gttcacctga gattgtcaaa 4140 tgcatctgag gcatgcagag gaagtgctgg gcacacagct agtgggaata cctcagcgta 4200 agtggccagg agatgccagg aatctccact atttcccttc cagtgtgcca gcctctgggt 4260 tttacaggcg catgtaattg cagtacctct gtgcacattt ccctactgcc tagaatgact 4320 ttcttgacta tccatgatat ataaaacaca gataccaaat tgttccctta cctcttcctc 4380 taggttcaag ttaatatgtt attggttgcc ttctataata tgttatctca ttgcctttcc 4440 caacaagtct ttgagataag tattaggtcc attttataga caaagagact gaggctcagc 4500 gagtaacttg gccaacaagt tgctcccact gctcaacagc aaatgagcgg tgggaccaaa 4560 attcaagcct gtgtctgttt aacttcaagc ctgtgaatgt actaaccggt gccctgtgcc 4620 agctagtact ttgctacagt cataacctag actgaagtga tagccatgcc cctaaaactc 4680 catgctgtgg tgacagcact gagcagtgtc caagaaggct tgacttctag gcctgtctct 4740 gccactcaca aactttataa gggaataaag tacatagcaa ggtccgccta gagttagtag 4800 cagttctgac aaagctgtaa tttgtcaata ttccgtcacc caacccagga atgctcattt 4860 ttaaggtatt tgactgaaac agttgagcat tgcccttcat atagtttaaa acagtggttt 4920 cagaaccact ttcctccaga ccatgggtgc tctgcaaggt gaatggagtt gtttcagaat 4980 gtttcaataa tcatccctac ctcattcgta agtggcatgt aatttttgca atcggaagat 5040 tttcataaac cctggatact aacctagact ggtttctata tcagatggtg gcttatttaa 5100 cataaaatta tgcattttac tatttcatgg tggatatatc aatatgttgt ggtcttttcc 5160 caatgaacac tttgattttc aggggttctg gaccctgaac atgggttaaa ccagtggttc 5220 tcaaggtgtg gtcttagcgc cagcagcatc tgcttcccct ggaaactttc tagaaatgca 5280 tattctcagg ccctcatgcc tgctgaatca gacactctgg gggtgggact cagccgtctg 5340 ttgtagcagt gcttccaggt tatcctgaca gtcactcaaa ttttagaacc actaggttct 5400 ctatatggga gagagtagtc tttgaacttg gaaaacaaga gaagctaaac ccctacagca 5460 agggctggtg accaggtcgt tgccagaacc tgaaagttcg cctctgtatt accgttcctg 5520 tccctaaccc aagtccttca gttctgggtg ctccagcaca cactgctttg tgctgcagtg 5580 atacaaatgt atggctcatc tccccagctg gcggggaggc atttaacaca ctgacttaat 5640 aaatatttat tgagtaaaag tatttgctcc taggaagcgg gatccaggta agcccttttt 5700 ttctctctca actgcttcta gcccagtgct ctttatgtag taagcactaa ataaacaact 5760 gctagatgtt gatccagaaa gtcacattcc ttctctaagc tttaagtttc tcatcttaaa 5820 aataagagga ttgtatcaga tggcttgcct taggtctctt tcagctccag agccccaaat 5880 accctatggt tctctattta gagatgttct tccccacaga ctgccataga actcctgtaa 5940 tttacttagt atttgcttga cagtatggag aagaaagggg agaatcaaga ttttatttaa 6000 aaaaaaagta gctagaatgt gtatatggtt cacaaaggta acaagaatta ttgacattct 6060 ttcttctctt ttttcttcct cttccttctc ttttcctcct tctcttcccc ctgcttctct 6120 cccttcttat agatgtgtca ccagcagttg gtcatctctt ggttttccct ggtttttctg 6180 gcatctcccc tcgtggccat atgggaactg aagaaagatg gtaaccagcc tctcattatt 6240 ctctgtggag gccccacttc taagccagga ctcttgggca gccactggtg ggaaatcaaa 6300 ctgaaatggg caaccatgca ctgggtcctc tagagaaagc catcactctg ggaaaatgca 6360 atgccatatc tctcttttct actttgatgg tatctatatt gtttggtttt cacattggat 6420 gacattggta cactatggtg gggaaagaca tatgatatat gatatggtgg ggaaagacat 6480 atgacatatg atattttcca atattactaa aaactgtttc acacaattaa aattccaaag 6540 tagaggattt gcaaagtata acaactgtgt tcgtttctca ttccaccaca tgatactgcc 6600 ccctcagttg gcactgtgat gacttacctc tgaccaagca ctttggagga agcataggat 6660 tcagactcac attgacttgg gttcaagtcc taggtctgtc aatgactggt tatgtgactt 6720 taagctgggt cacctctaat cctgaatttc ctcaactgta aactggatgt tacaaagtgg 6780 atgcctacca cgtgggttat ttagtgggtt aatgaatgca gaatacaact cgacagatag 6840 taaagtgaaa gtaaatgtca gctagtatta ctattttggt tgtttaaaat atctttcatg 6900 attcaagaga tactttttat tatcccaatg atcagtaaaa attattagta gactaataga 6960 atagttaatg gtaaaataag gagttctgcc catccttcta gtatctcaca ctcagtaaat 7020 gtgcattctg accgttggct gtacctgaaa gaccctcaga tttttatcac tgaagccaac 7080 atcataatgt tggcgattac tatctttaat tgtataataa taatagttaa tgtttattga 7140 gtgcactgtc tcacttaatt ctcacaagag ccatatgaag tagagactgt ctgtatccca 7200 ttttacagat gttggaaact gaggccagag agattaagta acttgcccaa tgtcacatac 7260 ctggtaaggg tggaacaggg acttgatccc aattctgtct tgcttcaaag ctggtgcact 7320 taaatttgtg aaaacgtttt tacaaggaca tgaagtaatt ttttcccagg tctttggaga 7380 gctgaataag aggaaatgga cataaattaa ggatgaaaat atttcagctg atgatcagaa 7440 ataatctttt gatattctag aaagtaccat cttgaaatgg gtacctgaaa gaaatctggg 7500 accactcctc tcttctcaag aattttagga agacagaatc cagccacccc ttctccatga 7560 gaatttgaga gatttagaca ctctcttaag taaaggcaaa ggcctgagcc aggggtatat 7620 ggcagatccc ttccaaccct gggattgtta gcgagctcag gaaccttggt cctggcatat 7680 ttgacccctt agtgacttct gatttggtaa accacagaaa ttccagaaaa tcagtgtgag 7740 aaactctctg aggtgtgact taggagggca gacgatgcag tgaggctaag tgccaggttc 7800 ttgatgctcc tcttcagctt tcctcctgca gctgttttcc ctgctgttga gcaaacatct 7860 tctagggctt ccgagcctca gttgggacag gaaagtaacc atgctcttca ggtgtcaggg 7920 ggacaaaaaa aaaaccaaga aaaagccaaa agtgccacat ggttttacat cagcacagct 7980 aatcatttcc ccagagttgg accccaaatg cttttgacct cttatttttg ttatccattc 8040 agtccttata atccaattga tgtaaagtga aaactttata ttctacaatg ctttacatcc 8100 agaggccaat aacgagaacc accatttata aagcatgtaa gggcactgtg tatgagctta 8160 tataatccac atatccacct tctaaagcaa gggctaatat ttttctcatt ttaaagatga 8220 tgacactgag gcttacagta gttgaatgtc ttgccaaagg ccacaagact ggagcaaggg 8280 ctagagctgc ttctaaatcc aggcctctgc cactccaaaa tgcaggctct caaccactgt 8340 gactcataaa cttgagcagg catcagcacc atctggagag cttaagaacc atataactaa 8400 atccatccca aggtttctga ttcagcagct gagaatttgc atttctgatc tattccaagg 8460 tgatgctgct gatggtgttt catcgatcat gctttgggaa ctactacatt aaacaattct 8520 attcaattaa taatttatgc atggattaaa aaaatgaatg aagctttgct atgacacact 8580 ctgaaatact atactaagcc attcctcaaa ggccagttta gacactagca ttaggcatcc 8640 cttgcaaagc ccaagagaca aaaggtctga gctatagccc ttgtacttct gacttgctgt 8700 gaccatgctt agatcgttgg cctcagtacg cttcttcatt aaatgggaag actaagctct 8760 actggactgc ttcataagag tgtaagatag ctaaaaataa taataataat aataataatg 8820 cagagagaat gaaaatctcc actggtgatt taaaacagag ggaacgaaat ccttaaatat 8880 ccatggaaaa ttgttaagag agtttctctg tacagttggc tgactcctcg gtctataagt 8940 aacgataact aacaccgaat ttactgtgtg gcagacactg tgctaagtac tttacgtgct 9000 tttttttttt ttcatttaat cctcagtcaa atgtaaggca gatactgtta ttattatcat 9060 tttacagatg aggaaactga ggctcatgat aatgaaatac cttgttccaa atcccccagc 9120 tggttagtgg agacaggatg acagtcttgg ttcgttgttc tcgacaccct gagcttttaa 9180 ccactatgtt actctgctga atattgtgcc ctgccgtatt ctctatgaaa ctgaaattgt 9240 gctggaagtt tctctccccc agacctttgg caaagagtct tgtgctgttt gcagtttttg 9300 gtatattaag gtgtttccaa tctgctaaat aatcaaaggt tactattaaa ggcagccttc 9360 cagtcaatga gtcgatggca gctataaaac tctttgtttc tcttttccat gaccttgagc 9420 ccaagcaggg tctcatgcct tgagatcatc tcagcaagca tttgccaaat acttgttgta 9480 aacaaggttg tgtttaggca atggggatgc ccgaagggtt aataaaacac agtcccagag 9540 ttcctggagc ttacagcctg gttctccact ttatgtgcat tccagtttat gtcgtagaat 9600 tggattggta tccggatgcc cctggagaaa tggtggtcct cacctgtgac acccctgaag 9660 aagatggtat cacctggacc ttggaccaga gcagtgaggt cttaggctct ggcaaaaccc 9720 tgaccatcca agtcaaagag tttggagatg ctggccagta cacctgtcac aaaggaggcg 9780 aggttctaag ccattcgctc ctgctgcttc acaaaaagga agatggaatt tggtccactg 9840 atattttaaa ggaccagaaa ggtaattcta tacccttgga tagtatcaat tttctctttc 9900 gctcataaga gttaaaaaca acaacaacaa caaattgaaa agccaagtca tggtgagtgt 9960 aatgaattaa catcaagtct cttattgatg ttaattgatg ttaacctcca ttttcctttg 10020 ctttcctgga ccctttgggt tatcaaccat caaaatctca tattaaggga gtttcatgat 10080 cagtctgaat gcttagcctc atgttttctt taaataatgg tgatattatt taatggctaa 10140 tggaaattaa ccgatagtgt atcactctgc actggggtga tagccttcaa aaaatgaatg 10200 cctctgccag gcatgttagg tgtgtagtgt actctgcaga atcaacaccc cactgggata 10260 ctcccaatcc ttatggagct acccaagagg caacgcatgg aagaacttca ccctgtacca 10320 tctggtgatc tgtgattcat cacaatcaaa acctttctgc aaaaaactcc taaatattga 10380 atttttgttt ttttcaaatc cagaacccaa aaataagacc tttctaagat gcgaggccaa 10440 gaattattct ggacgtttca cctgctggtg gctgacgaca atcagtactg atttgacatt 10500 cagtgtcaaa agcagcagag ggtgagtgaa actgctctgg tttctcagca tttttctaga 10560 actatttcat taagaaatta agggcaacct ctcagtgacc tatcagttaa tgataatggg 10620 aaaagcaaag tcaaacccgt gttttttcaa ccgcccttcc ttgtctacat tgaagaaaga 10680 acatggagat tttagccgat tgcttgaata aatgtatgtg ttggggcagg atattattgg 10740 gaactgagaa tagtctctgc tgtgtttgaa cccactcatc caaattgcct ggccatgctt 10800 cctgaagcct catagcacca aagaaaggga taaaaggaga attcaaagct acaaatgact 10860 tgctgaaatt gcaccttgag tcaaaaataa aaacaagagc tccagggcgt agatcttagg 10920 ggccctgaag cagactccaa aactcgatga ggcctcccga aattttccca gggccacctc 10980 aactcctttt acttctgctg acaccactaa tctgaagttc gctgttggtc caatgcacct 11040 ggactttccg taagaaagca acttccataa atacaagacc tatgtgttaa cccccatgtg 11100 gcttacttta atcatcaccg aagcaaaccc caggtgatca tcctgacttt accattattt 11160 cactgagtaa attaagcatt ggggtctcac tttttcatct ttaaaaggaa aatgcttact 11220 aaagaaatgt ttctccaagt gcataaagac ataatcagca gaggaatggt taaataaaac 11280 atggtacact atactcttgc ttaatgtgca gtcattgaag tggataaccc aacccatatg 11340 ttttgtcatg gagagctccc cataatatgt tcagagggga aaaggatggt tacataatca 11400 tatgtataca atttgatcct agttcataaa aataaaatct atatgtataa gtaaaatata 11460 tatagtggat atatataatg tagagatgta tataacatgg attatatata taatgtgtgt 11520 atacatatgt gtgtgtgtgt gtgtgtatat atatatatat atatataaaa tgtgtataca 11580 attatcttga atattcattg aaaaagttct ggccaggcac agtggctcac acctgaaatc 11640 ctaactcttt gggaggctga gacagaatga ttgcttgagg ccaggagttc aagaccagcc 11700 taggcaacac agtgagaccc catctcagaa aatattaaaa ataaaaaaat taggtgggtg 11760 tggtggcaca cacctgtagt cccagctact tgggaggcag agggagggga tcacttgagc 11820 ctaggagttt gaggctacag tggggtctga ttccaccact tcactccagc ctgggtggca 11880 gagcaaaacc ctgtctctta aaaaaaaaaa gagagagaga gagagaaaga aaaagaaaaa 11940 ggaaggtctg gaaggataca acaagctatt attagtactt aaacctgtgg agagcagtta 12000 aggatgaagg agacatacac ttctttcctt tatatggatc tttatcatct ttacttttat 12060 aattagtgtg tactgatttg tgtattgatt ttataattaa aatgggaaaa aatgaattta 12120 agtttttaac aagggggttt aataatcaga gattctagat ctaaaacaaa caaaaacttc 12180 catattcatt tagtccagag acatgtaagt gctcttgaat ttaagctttt tctcctgggg 12240 agggcagttt cttaccctct gggtagaaat cagcccagtt ggagaaactg tgtcctcaga 12300 caacagttga ggccttacct gccttactgg ctacaatcac taggaactct ctccccaatg 12360 tgtaacacag gctaatttct gtctttgact tcagctcttc tgacccccaa ggggtgacgt 12420 gcggagctgc tacactctct gcagagagag tcagagggga caacaaggag tatgagtact 12480 cagtggagtg ccaggaggac agtgcctgcc cagctgctga ggagagtctg cccattgagg 12540 tcatggtgga tgccgttcac aagctcaagt atgaaaacta caccagcagc ttcttcatca 12600 gggacatcag tgagttttgg atgattatat gtgctccata aggaaagata ctatttgtca 12660 cgtgttcaca atgccccatg cactgtgggg taggtggttg acaagcatca tctcttttat 12720 tctgcatcca aaaacaaaat acgatgtaga tactgttatc tgcattttaa ggaagaggaa 12780 attgagtctt agaaaagtta agcaacttgc cccagatctc agatcttaca gctagccgtt 12840 caaatccaga tccactccac tacagctgct ctttactgca ctttgattca gctgccagat 12900 agtttccatg atgaatccca gagcctaatc aagcataata ttcatattca gaaccagggc 12960 ttccttacta atggcaatta ttcccaacca atccttcctt agcatttgaa aagggacttc 13020 tttcttagaa tataaaccct tccaaaatgg acatcttttt ttttaattgg cagataggga 13080 tttcaccata agtcatttcc tttactattt attcattgac caggcagcat gataaagtgt 13140 aatagaacca gagaacttgc ttcaaaactt atggagggtt tgtacttggt gggtggggtc 13200 tagttcacat agggtggcca aggaaggcct ctctgaggag gtgacattta gctgacacca 13260 aaaggaaaga tgtcagttgt gttaagagca gagggaagca tatgtgcgaa gcacctgcta 13320 ggagccgtga tctttgtgtg gagcagtgcc aggcctacag agcccaacca cacaccctag 13380 catgtctctg cctcctctta tctagaagac ctaattgagg aaggagtctt tgtgaaactc 13440 actgctgtat ccttcatgca cagtccagtg gctggaacat aatgggcgct cagtattcat 13500 ggaataaaca agcaaattga gcatagagac aattgactgt aactgctcca agacatgtcc 13560 gcaccaaaag ctatgaaaag acaaaagaaa gggcagtaaa tagaaaatct atcatctcat 13620 ccccagggag aggctcagct tagttccatg ttcagtgcaa agtgagggat tagcacagac 13680 agggtggtcc ttcaatgcat ggcccataac cattaaagca gaggtcttct cactgtgcgg 13740 tcccatctga ttgttcagtg atgaggattc tgagcatctc tcagatcctg caatacatgt 13800 ggatctgaga tgtggccatt gataatgact gccttcccga ggcaccagcg tgagcacctg 13860 cggcagaggt gcctcacatt tgccagccag gtgctcacag aagttaagta actatccagt 13920 ggactcacag ctgatcaaag gtgcaagtga gatcataagc caaaaccact gaactccaaa 13980 gccttattag gaaaataaag catgtttatc ctcttccaca gtcaaacctg acccacccaa 14040 gaacttgcag ctgaagccat taaagaattc tcggcaggtg gaggtcagct gggagtaccc 14100 tgacacctgg agtactccac attcctactt ctccctgaca ttctgcgttc aggtccaggg 14160 caagagcaag agagaaaagg taagaagtga ttcaggtgca gtatattcct tggtcagttt 14220 tacggaggcc caccataaag tgagaagatg aatgatgata ataacaatga catccatgta 14280 tcacttaaca acagggatac attctgagaa attcatcttt aggcagctat atcattgtgc 14340 aaacatatat ggtgtaccca cacaaaccta gatggtatag cctactacgc ttctaggctt 14400 tatggtatag cctattgctc ctaggctgca aacctgtaca gcatgttcct gtactgaata 14460 ctgtaggcaa ttacaacaca atggtttgta tatctaaaca gaaaagatat agcaaaaata 14520 caatattata acaatatagg accactggtc atatatgtga tccttctttg actgaaatgt 14580 tattatgtga tgcataatta cttttcttag cacttttcta tgtgtctaga gctgtgccaa 14640 gggttttcca tgtttatttc acttaatcta caaaaattaa cgcaacaaag gtagctgatg 14700 ttattcttgt ttttttaccc ccttttttgt ggaaaagagg ctttcctttt ttccagaaac 14760 tgtggcaagg taaagtaaag ctgtagctga tgcaggaatt ttgtgtaggt gttagcagca 14820 ctgccctcac tacgtgctca ttggacagta gcccaacccc aagaaaagga tggttggtag 14880 ccagtagtat tatcatcatt tcacaagtga ttgaagactc agagaggtta agtgacttta 14940 ccaaggtcac ccagctagga aatgacataa ccaagacata aactcaatct gccagacaga 15000 aaggccatgc acctaaccac tccactacct ctgatgttgg tcattgatct tggcactcag 15060 aattagtcct gatagaggag acctgggctc cagaagccta aaattgttgt ttcaactgag 15120 tgcatgtaat gaatgataga acaggcaaga gatatcgccc ccaaaatgga tagctcctgg 15180 ctgttccaga tattataaaa ttattttact aaacagaatg tctacactta tagaggctaa 15240 gatattggct tcccagcttc ctcgccttac agcagaattc ctttgcctgt tgcaaggttc 15300 cagaggccct tttgtaccgc cccagactcc tttcacccca cttttaaaat cactggacaa 15360 agccctaatt cagcatagca tttagcatgt ggtagaaatt cagtgagcta gttactctct 15420 gggaaaataa ttaggtaggg aggctatcct ggaatagata tttacctaaa tattatttta 15480 catcttggca agtactttcc ctatttaaga tctgtatgac taataggtga tattgagtgc 15540 ttcctatgtg ctaaagactt gctaagagtt tgacgtgatt tttaccttga actataattc 15600 tatgaagtag gcattattgt tatccctatt tataagtgag gaaacagaca cagagaacct 15660 aagacatttt cctgaagtta cacagctatt aagtagcagt gccagaattt gaaggcaagt 15720 tttctgatga aatgatcagg atatggtatt tctcaatatc tcagggatgg ctagagcaaa 15780 tctgtctctc tctcaccatc agctcaggac tgggtgagtg gccatggggt cttgaggcaa 15840 ggcaattgtg ctagaaagat gaaagctggg ccaaacgatt tctccctcaa gggcttacaa 15900 agtacaaaag ctgcacctac atgtggagtg tctgccagta ggtggtgcaa gttctatgca 15960 cacccctgtg aattgcaagc acagtgccct aagaccaaga tgggcttgtt ttgggagagt 16020 atgcattgca gaaacaggct cagcttaccc tgtgactatg ttgccaaggg gtcttcacag 16080 ctttccttct cttttgcaga aagatagagt cttcacggac aagacctcag ccacggtcat 16140 ctgccgcaaa aatgccagca ttagcgtgcg ggcccaggac cgctactata gctcatcttg 16200 gagcgaatgg gcatctgtgc cctgcagtta ggtgagcagg ccctcaaagg ccagcccagg 16260 cctgcactct cagtgcacct ggatgcaggg atatgattgg gggctgtgtt ggagaggaaa 16320 gggggatgga gtggccagca cccagttgcc agaatcagaa acatacattt attcactaac 16380 agatatttat ttggtgcctt tgttatgtag gacactgtgc tggccacagg gatattgcag 16440 gaaagaaaac agaccggggt tctggcctcc taaagagaaa ggcaaagaaa agagagaggt 16500 agccaggagg cagagcatgg cggacttgca agcttgcagg actcagaatc ttgttctggg 16560 ggccccgggc cctgaaaccc actgaagggt tttcagcaag gaagtaacac aatcagatat 16620 tattttaaga aaaccctcaa gaaagcctct ggcaagcatg gtgccagcca aattccaggc 16680 cacataagga aggcctgggc cttctggcat gaaatccctg aaacccagtt gcccaggatc 16740 atatgttgtg agaaataaga agagacattg ctgttacaat gtcaccccac atcaactttt 16800 ggcattctct tccaggttct gatccaggat gaaaatttgg aggaaaagtg gaagatatta 16860 agcaaaatgt ttaaagacac aacggaatag acccaaaaag ataatttcta tctgatttgc 16920 tttaaaacgt ttttttagga tcacaatgat atctttgctg tatttgtata gttagatgct 16980 aaatgctcat tgaaacaatc agctaattta tgtatagatt ttccagctct caagttgcca 17040 tgggccttca tgctatttaa atatttaagt aatttatgta tttattagta tattactgtt 17100 atttaacgtt tgtctgccag gatgtatgga atgtttcata ctcttatgac ctgatccatc 17160 aggatcagtc cctattatgc aaaatgtgaa tttaatttta tttgtactga caacttttca 17220 agcaaggctg caagtacatc agttttatga caatcaggaa gaatgcagtg ttctgatacc 17280 agtgccatca tacacttgtg atggatggga acgcaagaga tacttacatg gaaacctgac 17340 aatgcaaacc tgttgagaag atccaggaga acaagatgct agttcccatg tctgtgaaga 17400 cttcctggag atggtgttga taaagcaatt tagggccact tacacttcta agcaagttta 17460 atctttggat gcctgaattt taaaagggct agaaaaaaat gattgaccag cctgggaaac 17520 ataacaagac cccgtctcta caaaaaaaat ttaaaattag ccaggcgtgg tggctcatgc 17580 ttgtggtccc agctgttcag gaggatgagg caggaggatc tcttgagccc aggaggtcaa 17640 ggctatggtg agccgtgatt gtgccactgc ataccagcct aggtgacaga atgagaccct 17700 gtctcaaaaa aaaaaatgat tgaaattaaa attcagcttt agcttccatg gcagtcctca 17760 cccccacctc tctaaaagac acaggaggat gacacagaaa caccgtaagt gtctggaagg 17820 caaaaagatc ttaagattca agagagagga caagtagtta tggctaagga catgaaattg 17880 tcagaatggc aggtggcttc ttaacagcca tgtgagaagc agacagatgc aaagaaaatc 17940 tggaatccct ttctcattag catgaatgaa cctgatacac aattatgacc agaaaatatg 18000 gctccatgaa ggtgctactt ttaagtaatg tatgtgcgct ctgtaaagtg attacatttg 18060 tttcctgttt gtttatttat ttatttattt ttgcattctg aggctgaact aataaaaact 18120 cttctttgta atcatatttt gggcattctc agctgatttg agtactctgc ttgcaagtct 18180 accaggggtg cattttttcc cctatcattt aagcattgcc ctttcttgaa gtgatcccat 18240 tccaaatttt gcagagttgc tctttcccct tatagtattt ccaaagtcag tgtcttcctg 18300 agctcagggg atgtccctgt aatctgacaa ggaaggatcc 18340 131 1263 DNA mammalian 131 atttgtattg tttgaagttt ttacaatagc atgtaatttt ctaagatttt aatttttata 60 agtacacatg gcttctcctt tatttgaaat gtgtactaga tgatcaaagc atatgcatgc 120 atgtattgct ttcttctagg agaaaataag tttttgtggc caaaaaaatt ctttaagtta 180 tttttggttt ttagggggtt gcctccatgt cacagcttaa tcatcagaca cattaacctt 240 gcagctcagc acgccctctg tttgtcagca gaccttcctc gcccataggg taagcaatag 300 aaagcttata ggtatcagtt tattttgcct gggatcaggg tctggattgg gaagtgggac 360 atgttgataa acctcttctc caaaattagg tcaatgggca tttggctcat attaccagaa 420 tgctggctgg ccatgtacag cctgtctccg agagaggctc taatgtggcc cccacattag 480 aacaacctgc caatgaccac attagaacct ccattgttaa aatgcaggtt cctgagcccc 540 atcccagatc tgaatcacaa tctccaagca tcagccccaa gaacctgaat tttgttgtta 600 catgcagata aagtacgaga accacttcct ccatgggtga actgaactta ccaaaatagt 660 cagtcccgag gggcagagat ggcgtaggtg ccagttcttc tttctcatcc tagatgctca 720 gagtcaaatt cttggctcag caatagacaa gtgatttcac tgcgggaaga caattcagag 780 ccctgttcca ggctcctcac attggatctc tctgtcttct tccactcctc tttgtcatct 840 ttgatgtccc cttgtgagct acgaaaagac tttctgggac acgacaggat aaaaaaataa 900 ataagtgcaa gctgccattc attaaacgtt tagccaggat gctgctttaa ctgcatccca 960 tcatatctca ttaatcttca caccagtcct gagatcaggt actattatta acccgatttt 1020 acagatgtga ggaactgagg cttaacgaag gtaagtaact tgcaggtgcg ggtatccagc 1080 tctctaactc cagagcccat gctcttaaaa ccctattact tgtccctggt gggaggtgaa 1140 cactgggggc cctttcatat aggactagcc ctcgggctgc aatctgagcg gaaaagggag 1200 gatgaggggc atacttcgaa gcttcttttg cataactggc gctgggattt ttactgagac 1260 ttt 1263 132 49 DNA mammalian 132 tgtacagcct gtctccgaga gaggctctaa tgtggccccc acattagaa 49 133 45 DNA mammalian 133 tgtacagcct gtctccgaga gagggctgtg gcccccacat tagaa 45 134 20 DNA mammalian 134 tagctcatct tggagcgaat 20 135 20 DNA mammalian 135 aacattccat acatcctggc 20 136 20 DNA mammalian 136 gccaggatgt atggaatgtt 20 137 20 DNA mammalian 137 gggtaagcga ttcaaacatt 20 138 21 DNA mammalian 138 ggtattgcat tgtaggcaca t 21 139 19 DNA mammalian 139 gggcaacaag agtgaaact 19 140 20 DNA mammalian 140 tcaaaagagg tccgtctaaa 20 

1. A method for determining the presence of a disease condition or a predisposition for the development of a disease condition in a mammalian animal said method comprising screening for the presence of a form of IL-12 p40 genetic sequence or derivative thereof or its expression product wherein the presence of said form of IL12 p40 genetic sequence or derivative thereof or its expression product is indicative of the presence of the disease condition or the propensity to develop said disease condition.
 2. A method for determining resistence to a disease condition in a mammalian animal said method comprising screening for the presence of a form of IL-12 p40 genetic sequence or derivative thereof or its expression product wherein the presence of said form of IL-12 p40 genetic sequence or derivative thereof or its expression product is indicative of resistance to developing said disease condition.
 3. The method according to claim 1 or 2 wherein said disease condition is characterised, exacerbated or otherwise associated with Th1/Th2 dysregulation.
 4. The method according to claim 3 wherein said form of IL-12 p40 genetic sequence comprises the Taq1⁺ or Taq1⁻ form of said sequence.
 5. The method according to claim 4 wherein said form of IL-12 p40 genetic sequence comprises the nucleotide sequence substantially as set forth in<400>1 or <400>2.
 6. The method according to claim 3 wherein said form of IL-12 p40 genetic sequence comprises a promoter region polymorphism.
 7. The method according to claim 6 wherein said form of IL-12 p40 promoter region sequence comprises the nucleotide sequence substantially as set forth in any one or more of <400>3, <400>4, <400>5, <400>6, <400>7, <400>8, <400>132 or <400>133.
 8. The method according to claim 3 wherein said form of IL-12 p40 genetic sequence comprises a polymorphism in exon
 6. 9. The method according to claim 8 wherein said form of IL-12 p40 exon 6 sequence comprises the nucleotide sequence substantially as set forth in any one or more of <400>9 or <400>10.
 10. The method according to claim 3 wherein said form of 1L-12 p40 genetic sequence comprises a polymorphism in exon
 7. 11. The method according to claim 10 wherein said form of IL-12 p40 exon 7 sequence comprises the nucleotide sequence substantially as set forth in any one or more of <400>11 or <400>12.
 12. The method according to claim 3 wherein said form of IL-12 p40 genetic sequence comprises a polymorphism in exon
 8. 13. The method according to claim 12 wherein said form of IL-12 p40 exon 8 sequence comprises the nucleotide sequence substantially as set forth in any one or more of <400>13-<400>14.
 14. The method according to claim 3 wherein said form of IL-12 p40 genetic sequence comprises a polymorphism in intron
 1. 15. The method according to claim 14 wherein said form of IL-12 p40 intron 1 sequence comprises the nucleotide sequence substantially as set forth in any one or more of <400>41-<400>48.
 16. The method according to claim 3 wherein said form of IL-12 p40 genetic sequence comprises a polymorphism in intron
 2. 17. The method according to claim 16 wherein said form of IL-12 p40 intron 2 sequence comprises the nucleotide sequence substantially as set forth in any one or more of <400>49-<400>52.
 18. The method according to claim 3 wherein said form of IL-12 p40 genetic sequence comprises a polymorphism in intron
 4. 19. The method according to claim 18 wherein said form of 1L-12 p40 intron 4 sequence comprises the nucleotide sequence substantially as set forth in any one or more of <400>55-<400>58.
 20. The method according to claim 3 wherein said form of IL-12 p40 genetic sequence comprises a polymorphism in intron
 7. 21. The method according to claim 20 wherein said form of IL-12 p40 intron 7 sequence comprises the nucleotide sequence substantially as set forth in any one or more of <400>59 or <400>60.
 22. The method according to any one of claims 3-21 wherein said disease condition is an autoimmune disease condition.
 23. The method according to claim 1 wherein said disease condition is IDDM and said form of 1L-12 p40 genetic sequence comprises the nucleotide sequence substantially as set forth in<400>2.
 24. The method according to claim 2 wherein said disease condition is IDDM and said form of IL-12 p40 genetic sequence comprises the nucleotide sequence substantially as set forth in <400>1.
 25. A method of determining the presence of a disease condition characterised by Th1/Th2 dysregulation or a predisposition to the development of a disease condition characterised by Th1/Th2 dysregulation in a mammalian animal said method comprising screening for the presence of an allelic form of IL-12 p40 genetic sequence or derivative thereof or its expression product wherein said allelic form of IL-12 p40 genetic sequence or derivative thereof is linked to another gene.
 26. The method according to claim 25 wherein said disease condition is an autoimmune disease condition.
 27. The method according to claim 26 wherein said IL-12 p40 genetic sequence comprises the nucleotide sequence substantially as set forth in <400>2 and said disease condition is IDDM.
 28. The method according to claim 27 wherein said other gene is a GABRA allele.
 29. The method according to claim 28 wherein said GABRA allele is the GABRA1-A allele.
 30. A method of determining resistance to a disease condition characterised by Th1/Th2 dysregulation in a mammalian animal said method comprising screening for the presence of an allelic form of IL-12 p40 genetic sequence or derivative thereof or its expression product wherein said allelic form of IL-12 p40 genetic sequence or derivative thereof is linked to another gene.
 31. The method according to claim 30 wherein said disease condition is an autoimmune disease condition.
 32. The method according to claim 31 wherein said IL-12 p40 genetic sequence comprises the nucleotide sequence substantially as set forth in <400>1 and said disease condition is IDDM.
 33. The method according to claim 32 wherein said other gene is a GABRA allele.
 34. The method according to claim 33 wherein said GABRA allele is the GABRA1-A allele.
 35. A kit for determining the presence of a disease condition or a predisposition to the development of a disease condition in a mammalian animal said kit comprising a means of detecting the presence or absence of a form of IL12p40 genetic sequence or derivative thereof ot its expression product.
 36. A kit for determining the presence of a disease condition or a predisposition to the development of a disease condition in a mammalian animal said kit comprising in compartmental form a first compartment adapted to contain an agent for detecting the Taq¹⁻ form of IL-12 p40 genetic sequence or derivative thereof or its expression product and a second compartment adapted to contain reagents useful for facilitating the detection by the agent in the first compartment.
 37. A kit for determining resistance to a disease condition in a mammalian animal said kit comprising in compartmental form a first compartment adapted to contain an agent for detecting the Taq+form of IL-12 p40 genetic sequence or derivative thereof or its expression product and a second compartment adapted to contain reagents useful for facilitating the detection by the agent in the first compartment.
 38. A method of treatment and/or prophylaxis of the disease condition characterised by Th1/Th2 dysregulation said method comprising administering to a mammal an effective amount of a form of IL-12 p40 genetic sequence or derivative, agonist or antagonist thereof or its expression product or derivative, antagonist or agonist thereof or a molecule which regulates the functioning of said IL-12 p40 genetic sequence wherein said IL-12 p40 or regulatory molecule thereof promotes resistance to said disease condition.
 39. The method according to claim 37 wherein said disease condition is IDDM and said IL-12 p40 genetic sequence comprises the nucleotide sequence substantially as set forth in <400>1. 